[COMPANY_011]  Dupi[INVESTIGATOR_902840]: LPS1 6677 Clinical study report  
16.1.1 Protocol and P rotocol Amendments 
This section includes the following:  
Amended Clinical Trial Protocol 02, dated 22 Sept 2022 
Page 1
Any and all information presented in this document shall be treated as confidential and shall remain the excl usive property of S anofi (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipi[INVESTIGATOR_21321], published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without th e prior wr itten 
consent of [COMPANY_011] (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the d ate 
of communication or afterwards (i) controls direc tly or indirectly [COMPANY_011] , (ii) is directly or indirec tly controlled by [CONTACT_13225] , with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capi[INVESTIGATOR_13040], partnership or o ther entity  
Based on Template: [COMPANY_011] OneDocument Version 2.0, dated 14-OCT -2019  Page 1 
AMENDED CLINICAL TRI AL PROTOCOL 02  
Protocol title:  A Phase 4,  randomized, double -blind, placebo -controlled, 
multicenter, parallel -group study  of the effect of  
dupi[INVESTIGATOR_902841]:  LPS16677  
Amendment number:  02 
Compound number 
(INN/Trademark):  SAR231893  
dupi[INVESTIGATOR_12458] /Dupi[INVESTIGATOR_12460]® 
Study p hase : Phase 4  
Short title:  Dupi[INVESTIGATOR_902842]:  [COMPANY_011] -Aventis Recherche & Développement  (SARD ) 
Legal registered 
address:  1 avenue Pi[INVESTIGATOR_12954] , 
[ZIP_CODE]  Chilly -Mazarin  
[LOCATION_009]  
Monitoring Team’s 
Representative Name 
[CONTACT_9352] 
[CONTACT_207969](s):  
IND: [ADDRESS_1266289]:  [ADDRESS_1266290]:  [STUDY_ID_REMOVED]  
WHO:  U1111 -1249 -6054  
EUDAMED  Not applicable  
Other:  Not applicable  
Date:  22-Sep-2022 Total number of pages:  106 
VV-CLIN-0587271 2.0Page 2[STUDY_ID_REMOVED]
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 2 PROTOCOL AMENDMENT S UMMARY OF CHANGES   
DOCUMENT HISTORY  
 
Document  Country/countries 
impacted by 
[CONTACT_13097], version  
Amended Clinical Trial protocol 02  All 22 September  2022, version 1 (electronic 2.0) 
Amended Clinical Trial protocol 01  All 17 September 2020, version 1 (electronic 1.0) 
Original Protocol   24 April 2020, version 1 (electronic 1.0)  
Amended protocol 02 (22 September  2022 ) 
This amended protocol (amendment 02) is considered to be non-substantial based on the criteria 
set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of 
the European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The main rationale for the Amendment is for the addition of  a virtual site (Metasite) that will 
enroll approximately 10 participants from  the [LOCATION_002] . The Metasite will be managed by 
[CONTACT_902897]37 (external vendor), using telemedicine (TM), mobile study nurses, and an electronic 
application (Science37 Platform). These 10 participants will undergo the same procedures and 
provide the same data as other trial participants  and will be conducte d at participants’ homes. The 
Investigational Medicinal Product (IMP) supply  process  for the participants enrolled by [CONTACT_902898] ( DTP ) has been detailed . Additionally, minor  clarifications and 
updates were included in the statistical sections, as per statistical analysis plan (SAP), and minor 
clarifications and corrections have been implemented across the document (see summary of 
changes table ). 
Protocol amendment summary of changes table  
Section # and Name  [CONTACT_11029]  
1.1 Synopsis ( Overall 
Design)  
4.1 Overall design  Added details on Science37 Metasite.  A Metasite has been added to support 
recruitment and decrease patient burden . 
Approximately  10 participants from the US will 
be enrolled by [CONTACT_902897]37  Metasite.  
1.1 Synopsis (overall design)  
4.1 Overall design  
Appendix 6: 
Polysomnography substudy  Added the information that the participants 
in the  will be enrolled in the 
US. Clarification . 
VV-CLIN-0587271 2.0Page 3

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 3 Section # and Name  [CONTACT_11029]  
1.1 Synopsis ((Statistical 
considerations; primary 
endpoint)  
9.4.2 Primary endpoint(s)  The text has been added to emphasize that 
the sleep disturbance score at Week 12 will 
be evaluated/measured in participants who 
discontinued the study in tervention not due 
to COVID -[ADDRESS_1266291] recent  data on exposure to 
Dupi[INVESTIGATOR_12458].  
2.3.2 Benefit assessment  Update the regulatory information.  Provided the updated data on regulatory 
information.  
5.1 Inclusion criteria (I 03)  The inclusion criterion was not changed; the 
initial definition of asthma exacerbation 
(deterioration of asthma that results in 
emergency treatment, hospi[INVESTIGATOR_902843], or treatment with systemic steroids) 
remains the same and refers to severe 
asthma exacerbation. Ther efore a 
clarification has been included.  Clarification of I03  
5.2 Exclusion criteria (E 03)  The exclusion criterion was not changed; the 
same clarification as for the I03 applies to 
E03. Clarification of E03  
6.1 Study intervention(s) 
administered  
6.2 Pre paration/handling/  
storage/accountability  Added the text on procedure of IMP supply , 
preparation, handling  and administration for 
the participants enrolled through Metasite.  Clarification on the IMP supply, handling and 
administration for the participants in Science37 
Metasite . 
6.1 Study intervention(s) 
administered  
6.5.[ADDRESS_1266292] asthma care for the treatment of 
severe exacerbations  Consistency of the information related to 
systemic corticosteroids across Section  6.5 
Concomitant therapy  
6.3 Measures to minimize 
bias: randomization and 
blinding  Added the procedure for obtaining the 
intervention kit numbers at randomization 
and subsequent visits via IVRS/IWRS calls 
considering the transportation lead time for 
Science37 Metasite.  To facilitate the participants by [CONTACT_902897]37 
Metasite to perform the study procedures at’ 
home.  
6.4 Study intervention 
compliance  Added text regarding IMP/intervention 
accountability by [CONTACT_902897]37  for Science37 
Metasite.  To facilitate the participants enrolled by 
[CONTACT_902897]37 Metasite to perform the study 
procedures at home.  
VV-CLIN-0587271 2.0Page 4
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 4 Section # and Name  [CONTACT_11029]  
[ADDRESS_1266293] of pre -BD 
FEV 1. To highlight that pre -BD FEV1 can be retested 
one additional time during screening period in 
case of unsuccessful spi[INVESTIGATOR_902844]1.  
8.1.9 Asthma control 
questionnaire 7 -question 
version  7-point scale for FEV1% prediction was 
added.  Clarification of text.  
8.1.10 Asthma quality of life 
questionnaire with 
standardized activities (self -
administered) (≥12 years)  Clarification added on the overall score.  Clarification of text.  
8.3.[ADDRESS_1266294] common approach, and this is 
aligned with [COMPANY_011] standards.  
9.4.3 Secondary endpoint(s)  Deleted the word “weekly average” from the 
first secondary endpoint.  This was a typo and edited to correct the 
description of the timeline to monthly average, 
which is how the endpoint is correctly 
presented throughout the rest of the document.  
10.1.[ADDRESS_1266295]  
of study procedures remotely.  
VV-CLIN-0587271 2.0Page 5
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 5 Section # and Name  [CONTACT_11029]  
10.2 Appendix 2: Clinical 
laboratory tests  Added text regarding blood sample 
collection and pregnancy tests (if applicable) 
by [CONTACT_902897]37 for Science37 Metasite.  To facilitate the participants enrolled by 
[CONTACT_902897]37 Metasite to perform the study 
procedures at  home . 
10.3.1 Definition of AE  Added the definition of unsolicited and 
solicited AE  Information added based on new protocol 
template  
10.7 Appendix 7: Virtual 
Metasite  Additional appendix (Appendix 7) on 
Science37 Metasite added. Subsequent 
appendices were re -numbered.  A Metasite has been added to facilitate conduct  
of study procedures remotely.  Approximately  
[ADDRESS_1266296] “treatment” modified to “study 
intervention”/ “intervention” wherever 
applicable.  To maintain consistency throughout the 
protocol.  
Whole document  Minor formatting, typo corrections, 
consistency, and clarification changes.  Consistency.  
 
VV-CLIN-0587271 2.0Page 6
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266297] OF FIGURE S ................................ ................................ ................................ ................................ ........  10 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...............  11 
1.1 SYNOPSIS  ................................ ................................ ................................ ................................ ..... 11 
1.2 SCHEMA  ................................ ................................ ................................ ................................ ........  17 
1.3 SCHEDULE OF AC TIVITIES (SOA)  ................................ ................................ ..............................  18 
2 INTRODUCTION  ................................ ................................ ................................ ............................  23 
2.1 STUDY RATIONALE ................................ ................................ ................................ ......................  23 
2.2 BACK GROUND  ................................ ................................ ................................ .............................  24 
2.3 BENEFIT/RISK ASSESSM ENT ................................ ................................ ................................ ..... 25 
2.3.1  Risk assessment  ................................ ................................ ................................ ............................  25 
2.3.2  Benefit assessment  ................................ ................................ ................................ ........................  27 
2.3.3 Benefit/risk assessment related to COVID -19 ................................ ................................ ...............  28 
2.3.4  Overall benefit: risk conclusion  ................................ ................................ ................................ ...... 28 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ ................................ . 29 
3.1 APPROPRIATENESS OF M EASUREMENTS  ................................ ................................ ..............  30 
4 STUDY DESIGN  ................................ ................................ ................................ ............................  31 
4.1 OVERALL DESIGN  ................................ ................................ ................................ ........................  31 
4.2 SCIENT IFIC RATIONALE FOR S TUDY DESIGN  ................................ ................................ .........  32 
4.2.1  Participant input into design  ................................ ................................ ................................ ...........  33 
4.3 JUSTIFICATION FOR DO SE ................................ ................................ ................................ ........  33 
4.4 END OF STUDY DEFINIT ION ................................ ................................ ................................ ....... 33 
5 STUDY POPULATION  ................................ ................................ ................................ ..................  34 
5.1 INCLUSION CRITERIA  ................................ ................................ ................................ ..................  34 
VV-CLIN-0587271 2.0Page 7
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 7 5.2 EXCLUSION CRITERIA  ................................ ................................ ................................ ................  36 
5.3 LIFESTYLE CONSIDERAT IONS  ................................ ................................ ................................ ... 38 
5.4 SCREEN FAILURES ................................ ................................ ................................ ......................  39 
5.5 CRITERIA FOR TEMPORA RILY DELAYING SCREEN ING, RANDOMI ZATION, OR 
STUDY INTERVENTION A DMINISTRATION  ................................ ................................ ...............  40 
6 STUDY INTERVENTION  ................................ ................................ ................................ ...............  41 
6.1 STUDY INTERVENTION(S ) ADMINISTERED  ................................ ................................ ..............  41 
6.1.1  Devices  ................................ ................................ ................................ ................................ ..........  44 
6.2 PREPARATION/HANDLING /STORAGE/ACCOUNTABIL ITY................................ .......................  44 
6.3 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND BLINDING  ................................ ....... 44 
6.4 STUDY INTERVENTION C OMPLIANCE  ................................ ................................ ......................  46 
6.5 CONCOMITANT THERAPY  ................................ ................................ ................................ ..........  47 
6.5.1 Rescue medicine  ................................ ................................ ................................ ............................  47 
6.6 DOSE MODIFICATION  ................................ ................................ ................................ ..................  48 
6.7 INTERVENTION AFTER T HE END OF THE STUDY  ................................ ................................ ... 48 
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ...........................  49 
7.1 DISCONTINUATION OF S TUDY  INTERVENTION  ................................ ................................ ...... 49 
7.1.1  Definitive discontinuation  ................................ ................................ ................................ ...............  49 
7.1.2  Temporary discontinuation  ................................ ................................ ................................ .............  50 
[IP_ADDRESS]  Rechallenge  ................................ ................................ ................................ ................................ ... 51 
7.2 PART ICIPANT DISCONTINUAT ION/WITHDRAWAL FROM THE STUDY  ................................ .. [ADDRESS_1266298]  ................................ ................................ ................................ .............................  56 
8.1.5 Asthma sleep disturbance questionnaire  ................................ ................................ .......................  56 
8.1.6  Asthma daytime symptom diary - Asthma nighttime symptom diary  ................................ .............  57 
8.1.7  Sleep diary  ................................ ................................ ................................ ................................ ..... 57 
VV-CLIN-0587271 2.0Page 8
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 9 9.4 STATISTICAL ANALYSES  ................................ ................................ ................................ ............  69 
9.4.1  General considerations  ................................ ................................ ................................ ..................  69 
9.4.2  Primary endpoint(s)  ................................ ................................ ................................ ........................  70 
9.4.3  Secondary endpoint(s)  ................................ ................................ ................................ ...................  70 
9.4.4  Tertiary/exploratory endpoint(s)  ................................ ................................ ................................ ..... 71 
9.4.5  Other safety analyse(s)  ................................ ................................ ................................ ..................  71 
9.4.6  Other analyse(s)  ................................ ................................ ................................ .............................  71 
9.5 INTERIM ANALYSES  ................................ ................................ ................................ ....................  72 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS  ........................  73 
10.1  APPENDIX 1: REGULATO RY, ETHICAL, AND STU DY OVERSIGHT CONSIDE RATIONS  ....... 73 
10.1.1  Regulatory and ethical considerations  ................................ ................................ ...........................  73 
10.1.2  Financial disclosure ................................ ................................ ................................ ........................  74 
10.1.3  Informed consent process  ................................ ................................ ................................ ..............  74 
10.1.4  Data protection  ................................ ................................ ................................ ...............................  75 
10.1.5  Dissemination of clinical study data  ................................ ................................ ...............................  77 
10.1.6  Data quality assurance  ................................ ................................ ................................ ..................  78 
10.1.7  Source documents  ................................ ................................ ................................ .........................  78 
10.1.8  Study and site start and closure  ................................ ................................ ................................ ..... 79 
10.1.9  Publication policy  ................................ ................................ ................................ ...........................  80 
10.2 APPENDIX 2: CLINICAL  LABORATORY TESTS  ................................ ................................ .........  80 
10.3  APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND REPO RTING  ................................ ................  81 
10.3.1  Definition of AE  ................................ ................................ ................................ ..............................  81 
10.3.2  Definition of SAE  ................................ ................................ ................................ ............................  83 
10.3.3  Recording and follow -up of AE and/or SAE  ................................ ................................ ...................  84 
10.3.4  Reporting of SAEs ................................ ................................ ................................ ..........................  86 
10.4  APPENDIX 4: CONTRACE PTIVE GUIDANCE AND C OLLECTION OF PREGNAN CY 
INFORMATION  ................................ ................................ ................................ ..............................  86 
10.5  APPENDIX 5: LIVER AN D OTHER SAFETY: SUGG ESTED ACTIONS AND FO LLOW -UP 
ASSESSMENTS  ................................ ................................ ................................ ............................  90 
10.6  APPENDIX 6: POLYSOMN OGRAPHY SUBSTUDY  ................................ ................................ ..... 91 
10.7  APPENDIX 7: SCIENCE3 7 METASITE  ................................ ................................ .........................  93 
10.8  APPENDIX 8: CONTINGE NCY MEASURES FOR A R EGIONAL OR NATIONAL 
EMERGENCY T HAT IS DECLARED BY A  GOVERNMENTAL AGENCY  ................................ ... 95 
VV-CLIN-0587271 2.0Page 10
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 11 1 PROTOCOL SUMMARY   
1.1 SYNOPSIS   
Prot ocol title:  A Phase 4, randomized, double -blind, placebo -controlled, multicenter, parallel -
group study of the effect of dupi[INVESTIGATOR_902845]:  Dupi[INVESTIGATOR_902846]:  
Asthma is a chronic inflammatory disease of the airways characterized by [CONTACT_902899], acute and chronic bronchoconstriction, airway edema, and mucus plugging. 
The inflammatory component of asthma involves many cell types, including mast cell s, 
eosinophils, T -lymphocytes, neutrophils, and epi[INVESTIGATOR_902847]. For 
most asthma patients, a regimen of controller therapy and reliever therapy provides adequate 
long-term control.  
The prevalence of any sleep disturbance is higher in participants with uncontrolled asthma than 
with controlled or partially controlled asthma (32.2% versus  19.9% and 20.1% respectively, 
p <0.001). Poorer sleep quality in severe and non -severe asthma was suggested by [CONTACT_902900] (SARP ). Poor sleep 
quality was associated with worse asthma control and quality of life in patients with both severe 
and non -severe asthm a (1). Poor asthma control is more common in the presence of any sleep 
disturbance (22.7 versus  13.7%, p  <0.001)  (2). Sleep disturbances and inability to consolidate 
sleep often result in excessive daytime sleepi[INVESTIGATOR_902848], 
asthma control, quality of life , and c ognitive impairment, which may lead to social and 
neurobehavioral problems (3, 4, 5, 6, 7). In addition, t he nighttime asthma symptom exacerbation s 
are likely due to increased lower  airway resistance and dec reased nocturnal expi[INVESTIGATOR_10229] (8, 9, 
10). Since sleep disturbances adversely affect overall patient quality o f life, accurate detection and 
monitoring of their manifestation is important to the management of asthma ( 11). Therefore, o ne 
of the asthma treatment goals is to eliminate asthma symptoms at night and decrease awakenings 
due to asthma symptoms. Better control of nocturnal asthma symptoms could lead to improved 
sleep quality and a decrease in daytime sleep -related symptoms (12). 
Dupi[INVESTIGATOR_24783] a human monoclonal antibody (mAb ) directed against the interleukin -4 receptor 
alpha (IL-4Rα) subunit, a component of interleukin (IL )-4 receptors Type I and Type  II. The 
IL-4 receptors mediate the IL -4 signaling (both Type  I and Type  II) and IL -13 signaling ( Type  II). 
Both IL -4 and IL -13 signaling pathways are thought to play key roles in the pathophysiology of 
Type 2 inflammatory diseases.  Dupi[INVESTIGATOR_902849] -to-severe asthma in the  [LOCATION_002]  (US) , and for the treatment of patients with severe 
asthma in Europe and Japan.  
In dupi[INVESTIGATOR_902850], around 60% of patients had sleep disturbances based on the number 
of nocturnal awakenings reported at baseline . 
VV-CLIN-0587271 2.0Page 12
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266299] of dupi[INVESTIGATOR_902851], leading to better asthma control and overall improved quality of life . 
Objectives and endpoints  
 
Objective s Endpoint s 
Primary  
• To assess the effect  of dupi[INVESTIGATOR_902852]  • Change from baseline to Week 12 in sleep disturbance  score 
using the Asthma Sleep Disturbance Questionnaire  
Secondary  
• To evaluate the effect of dupi[INVESTIGATOR_902853]  • Change from baseline to Week 12 on the number of 
nocturnal awakenings (Sleep Diary)  
• Change from baseline to Week 12 in Patient  Reported 
Outcomes Measurement Information System (PROMIS ) 
Sleep-Related Impairment 8a scale  
• Change from baseline to Week 12 in sleep quality  (Sleep 
Diary)  
• Change from baseline to Week 12 in restorative sleep  (Sleep 
Diary)  
• Change from baseline to Week 12 in wake after sleep onset 
(WASO ) (Sleep Diary)  
• To evaluate t he effect of dupi[INVESTIGATOR_902854]  • Change from baseline to Week  12 in WASO based on 
actigraphy data  
• To evaluate the effect of dupi[INVESTIGATOR_902855]  • Change from baseline to Week 12 in Asthma Daytime 
Symptom Diary (ADSD ) and Asthma Nighttime Symptom 
Diary (ANSD ) 
• To evaluate the effect of dupi[INVESTIGATOR_902856]  • Change from baseline to We ek 12 in prebronchodilator 
forced expi[INVESTIGATOR_12194] (pre -BD FEV 1) 
• To evaluate the safety of dupi[INVESTIGATOR_12458]  • Incidenc e of treatment -emergent adverse events (TEAE s) 
and serious adverse events (SAE s) including clinically 
significant changes in vital signs  
• Incidence of adverse events of special interest (AESI)  
Overall design:  
This is a  Phase 4 , randomized 1:1, multicenter study with [ADDRESS_1266300] of dupi[INVESTIGATOR_902857] , asthma control, and health -related quality of life  (HRQoL) , and in reducing daytime 
and nighttime asthma symptom s. 
VV-CLIN-0587271 2.0Page 13

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 14 Intervention  groups and duration:  
Study intervention groups:  
Participants who satisfy the inclusion and exclusion criteria will be randomized centrally (1:1) to 
one of the following investigational medicinal product ( IMP) treatment groups:  
• Dupi[INVESTIGATOR_12458]  200 mg every 2 weeks ( Q2W ). 
• Matching placebo . 
Duration of study period (per participant):  
Study duration per participant  will be approximately 16 weeks and up to 29  weeks.  
The study includes 3 study periods:  
• Screening period :  
- Screening Period 1: Day -35 to Day -12, from signed informed conse nt. 
- Screening Period 2 ( Pre-baseline assessments): participant s eligible to continue will 
complete the assessments specified in the schedule of activities ( SoA) from Day -11 to 
Day -1 (right before Day 1).  
- If preferred by [CONTACT_902901], screening visit 1  
(SV1) and screening visit 2  (SV2)  can be merged  into a  single on -site visit. 
Importantly, this single screening visit will have to be done on Day -[ADDRESS_1266301] . 
• Randomized, placebo -controlle d treatment period : 12 weeks from baseline (Day  1). 
• Post-treatment follow -up period : up to 12 weeks or until the participant  switch es to 
commercialized dupi[INVESTIGATOR_12458] (or other biologic product), which ever comes first.  
Study intervention (s) 
Investigational medicinal product(s)  
Dupi[INVESTIGATOR_12458] 200 mg and placebo matching dupi[INVESTIGATOR_12458] 200 mg supplied in visually 
indistinguishable prefilled syringes . 
Dupi[INVESTIGATOR_12458]  
• Formulation:  Dupi[INVESTIGATOR_12458] 200 mg: a 175 mg/mL dupi[INVESTIGATOR_125314] a prefilled syringe 
to deliver 200 mg in a 1.1 4 mL injection . 
• Route(s) of administration:  subcutaneous (SC ) injection . 
• Dose r egimen : one injection of 200 mg Q2W after an initial loading dose of 400  mg 
(2 injections of 200 mg) on Day 1 . 
VV-CLIN-0587271 2.0Page 15
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 15 Placebo  
• Formulation: Placebo matching dupi[INVESTIGATOR_12458] 200 mg: identical formulation to the active 
200 mg formulation without dupi[INVESTIGATOR_12458], in a prefilled syringe to deliver placebo in a 
1.14 mL injection . 
• Route(s) of administration: SC injection . 
• Dose regimen: one injectio n of placebo matching dupi[INVESTIGATOR_12458] 200 mg Q2W after an initial  
matching placebo  loading dose  of 400 mg  (2 injections of placebo matching dupi[INVESTIGATOR_12458] 
200 mg) on Day  1. 
Noninvestigational medicinal products(s)  
Background  asthma  therapy with medium to high dose of ICS in combination with a second 
controller medication (eg, long-acting β2 agonist [LABA ], leukotriene receptor antagonist 
[LTRA ) at a stable dose  ≥1 month prior to SV1 and during the screening period ( Table  3). 
Participants requiring a third controller for their asthma will be considered eligible for this study, 
also at a stable dose ≥1 month prior to SV1 and during the screening period . Theophylli ne is not 
allowed because  it can interfere with sleep and may confound the study assessments.  
• Formulation and route(s) of administration: refer to label . 
• Dose regimen: as prescribed . 
The asthma background therapy should be maintained at a stable dose during the study treatment 
period.  
Posttrial access to study medication  
Posttrial access to study medication will be assessed in accordance to the country requirements 
and the legislation in place.  
Statistical considerations:  
• Primary endpoint : The primary  endpoint will be analyzed using a mixed -effect model 
with repeated measurement (MMRM ) approach. The model will include change f rom 
baseline in sleep disturbance  score up to Week 12 as response variables, and treatment, 
age, body mass index (BMI ), stratification factors , visit, treatment -by-visit interaction, 
baseline Asthma Control Questionnaire -5 (ACQ -5), baseline sleep distu rbance  score and 
baseline -by-visit interaction as covariates. An unstructured correlation matrix will be used 
to model the within -participant  errors. Parameters will be estimated using restricted 
maximum likelihood method with the Newton -Raphson algorithm.  No imputations for 
missing values will be carried out. To mitigate the risk of potential different responses 
based on the Sleep Disturbance Questionnaire before and after amendment  01, the primary 
analysis of change from baseline in sleep disturbance scor e will exclude the participants 
who use the original questionnaire at baseline and/or post -baseline.  
Statistical inferences on treatment comparisons for the change from baseline in sleep 
disturbance  score at Week [ADDRESS_1266302] 
square s (LS) mean of each treatment group, difference in the LS mean between the 
VV-CLIN-0587271 2.0Page 16
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 16 dupi[INVESTIGATOR_125316], and the corresponding 95%  confidence interval (CI ) of the 
differences and p -values will be provided. For participants discontinuing the study 
intervention before Week [ADDRESS_1266303], for any participants discontinuing the study intervention due to the COVID -19 
pandemic, off -treatment  data will not be included (i.e., set to missing) but will b e assumed 
missing at random . 
• Main  secondary endpoints:  The change from baseline in the continuous endpoints to 
Week 12 will analyzed using the MMRM model in the same fashion as for the primary 
endpoints  based on the intent -to-treat (ITT) population . For th e spi[INVESTIGATOR_270942], the 
model will also include sex and baseline height as the covariates.  
Data Monitoring Committee: No  
VV-CLIN-0587271 2.0Page 17
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] Group - strictly confidential  Page 17 1.2 SCHEMA   
Figure  1 - Graphical study design   
 
* An interim analysis will be performed to re-estimate sample size when 50% of  participant s (approximately 130)  reach Week 12 visit  or discontinue the study . 
D1: Day 1; ICF : informed  consent form; Q2W : every 2 weeks; R: randomization; SV: screening visit; V: visit. 
VV-CLIN-0587271 2.0
Page 18
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266304] at screening visit ( SV1) and urine pregnancy tests at the other visits using dipstick. A WOCBP must have a negative highly sensitive pregnancy test at SV1 (serum pregnancy test) and on 
Day [ADDRESS_1266305] dose of study intervention (urine or serum, if required by [CONTACT_427]) . If a urine test on Day 1 cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is 
required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive . In case of positive urinary test during the study, a serum pregnancy test should be performed 
as soon as possible to confirm the pregnancy. A urine pregnancy test will be performed at h ome at the follow -up visit.  
h Hepatitis screening covering hepatitis B surface antigen (HBs Ag), total hepatitis B core antibody (total HBcAb); hepatitis C  virus antibodies (HCVAb). In case of results showing HBsAg (negative) and HBcAb 
(positive), HBV DNA te sting will be performed to rule out a false positivity or to clarify the serological status if the Investigator finds it uncl ear to interpret in absence of known HBV infection. In case of results 
showing HCVAb (positive), HCV RNA testing may be performed t o rule out a false positivity. Human Immunodeficiency Virus screening (Anti -HIV-1 and HIV -2 antibodies).  Tuberculosis testing will be performed 
only on a country by [CONTACT_902902].  
i Retesting of eosinophil count is allowed up to three times during the screening period to meet inclusion criteria for showing  eosinophil count ≥150 cells/microliter cells/mL ( I 04) before randomization. This is only 
required if the participant  doesn’t have the blood eosinophil count measured within [ADDRESS_1266306] administrations (Q2W) should be separated by [CONTACT_2669] 11 days. The administration is performed on -site during planned visits alternating with Q2W home administration ( participant , 
caregiver, or health care professional) or in a hea lth care facility. On Day 1, loading dose as follows:  400 mg  dupi[INVESTIGATOR_902858] (200 mg x 2 syringes  injections)  and 2 placebo syringes for the 
placebo arm.  Science37  Metasite: Investigational product  (IMP)  administrations will be done at part icipant's home by [CONTACT_902897]37  home nursing service.  
k Should be completed by [CONTACT_3445] s regularly to record investigational  (home dosing diary)  and non -investigational  (asthma background therapy  diary)  product information. Recorded data will be collected by [CONTACT_902903] -site visit.  
l Retesting of can be performed one additional time during screening if the eligibility criterion for was not met at SV1.  will be rechecked at randomization visit (V2) for eligibility.  It will be perform ed 
after a wash -out period of bronchodilators according to their action duration.  Further details on the procedure will be provided in a separate instruction manual.  
m Spi[INVESTIGATOR_902859], in the morning if possible.  If testing can only be done at another time during the day, then the testing should be done at approximately the same time 
of day at each visit throughout the study. Spi[INVESTIGATOR_208460] a wash -out period of bronchodilators according to thei r action duration. This will be verified before performing the measurements. A 
participant who is unable to complete a successful spi[INVESTIGATOR_902860] 2005 ATS criteria or evaluated by [CONTACT_902904] f or pre -BD FEV1 at SV1 can be retested 
one additional time during the screening period of the study. For spi[INVESTIGATOR_902861] 1 local values from SV1 and V isit 2 before randomization (the results from 
centr al reading will not be available on the same day).  Further details on the procedure will be provided in a separate instruction manual.   
n 3 attempts may be performed during the screening period to meet the eligibility  criteria for reversibility before random ization.  
o Actigraphy: The participants will complete baseline assessments from Day -11 to Day -1 (right before Day 1); daily assessment thereafter until Week 4; then only the week before a clinical visit until EOT. Basel ine 
value will be calculated using th e data from Day -7 to Day -1. Science37 Metasite: For the completion of the baseline and postbaseline assessments, refer to Appendix 7 ( Section  10.7). 
p  
 
 
q Each participant in this substudy will have a total of  two overnight : [ADDRESS_1266307] baseline data and 1  more at Week 12 . If the sleep recording is inadequate 
as judged by [CONTACT_902905], the at -home sleep assessment will be repeated within 1 week of the original assessment.  
r Science37  Metasite:  participant randomization in IVRS/IWRS will occur on Day  1, with first loading dose occurring up to [ADDRESS_1266308] randomization to account for the lag between IVRS/IWRS randomization trigger 
for IMP DTP shipment and IMP availability to participant/mobile study nurse . 
s Science37  Metasite:  the windows for subsequent at home dosing  visits (week 4, week 8, week 12), up to 3 days (maximum visit window) to account for the lag between IWRS trigger for IMP DTP shipment and 
IMP availability to participant/mobile study nurse . 
ACQ -5: Asthma Control Questionnaire -5;  AD: atopic dermatitis; ADSD: Asthma Daytime  Symptoms Diary; AE : adverse event; AESI: adverse event of special interest; ALT: 
alanine transaminase; ANSD: A sthma Nighttime Symptoms Diary;  ATS: American Thoracic Society; BD : bronchodilator; 
CRSw /sNP; chronic rhinosinusitis wit h/without nasal polyps ; D: day; E/D : early discontinuation; ECG : electrocardiogram; EOS : end of st udy; EOT : end of treatment; ESD: early study discontinuation; ETD: early 
treatment discontinuation; e; FEV 1: forced expi[INVESTIGATOR_12194]; HBcAB : hepatitis B core antibody; HBsAg: hepatitis B surface antigen; HBV : hepatitis B virus; HCV : hepatitis C virus; 
HCVAb: hepatitis C v irus antibody; HIV: human immunodefi ciency virus; IMP: investigational medicinal product; IVRS: interactive voice response system ; IWRS: interactive web response system; OCS : oral 
corticosteroid;  PRO: patient -reported outcome;  PROMIS: patient -reported outcome measurement information system;  
RNA : ribonucleic acid;  SAE: serious adverse event; TB: tuberculosis; W: week; WOCBP: woman of childbearing potential ; .
VV-CLIN-0587271 2.0
Page 23

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266309] asthma patients, a regimen of controller therapy and reliever therapy provides adequate long -
term control .  
Respi[INVESTIGATOR_902862]. Difficulties inducing sleep, sleep 
fragmentation, early morning  awakenings , and daytime sleepi[INVESTIGATOR_902863] (13). 
Dupi[INVESTIGATOR_12458], a fully human monoclonal antibody, is directed against the IL -4Rα subunit , which is a 
component of IL -4 heterodimeric receptors Type I (IL4 -ligand only) and Type II (both IL -4 and 
IL-13 ligands). The binding of dupi[INVESTIGATOR_209320] -4Rα results in blockade of downstream signaling 
initiated by [CONTACT_485864] -4 and IL -13. These cytokines play  key roles in the pathogenesis of various 
allergic diseases including asthma (14). The results of dupi[INVESTIGATOR_902864] -to-severe asthma patients by [CONTACT_902906], improving the lung function and asthma control (15), reducing oral 
glucocorticoid use (16) as well as decreasing  disturbance measured by [CONTACT_902907] . 
Dupi[INVESTIGATOR_902865] (≥12 years) with moderate -to-
severe eosinophilic asthma and in the European Union ( EU) for use in adults and adolescents 
(≥12  years) with severe asthma with Type 2 inflammation. In Japan, dupi[INVESTIGATOR_902866] (PMDA ) approval for use in adults and adolescents 
(≥12 years) with severe or refractory bronchial asthma . 
2.1 STUDY RATIONALE   
Sleep is a significant dimension of a patient’s life and the long -term interruption of normal 
sleepi[INVESTIGATOR_902867], emotional functioning an d quality of life (17, 18, 19, 
20) as well as increases the risk for poor health outcomes and psychological distress (21, 22). 
In addition, poorer sleep quality in severe and non -severe asthma was suggested by [CONTACT_902908]. Poor sleep quality was associated with worse 
asthma control and quality of life in patients with both severe and non -severe asthma ( 1). Sleep 
disturbances and inability to consolidate sleep often result in excessive daytime sleepi[INVESTIGATOR_902868], asthma control, quality of life, and to cognitive 
impairment, which may lead to social and neurobehavioral problems (3, 4, 5, 6, 7).  
VV-CLIN-0587271 2.0Page 24
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 24 The prevalence of any sleep disturbance is higher in participants with uncontrolled asthma than 
with controlled or partially controlled asthma (32.2% versus  19.9% and 20.1% respectively, 
p <0.001). There is no significant difference in prevalence of sleep disturbances between subjects 
with controlled asthma and subjects without asthma. Poor asthma control is more common in the 
presence of any sleep disturbance (22.7 % versus  13.7%, p  <0.001)  (2). The nighttime asthma 
symptom exacerbations are likely due to increased lower  airway resistance and decreased 
nocturnal expi[INVESTIGATOR_10229] ( 8, 9, 10). 
Since sleep disturbances adversely affect overall patient quality of life, accurate detection and 
monitoring of their manifestation is important to the management of asthma (11). 
One of the asthma treatment goals is to eliminate asthma symptoms at night and decrease 
awakenings due to asthma symptoms. Better control of nocturnal asthma symptoms could lead to 
impr oved sleep quality and a decrease in daytime sleep -related symptoms (12). 
A recently published observational study assessing sleep quality in  patients with asthma (N=1150) 
showed that 58% of the patients had impaired sleep quality (P ittsburgh Sleep Quality Index  
[PSQI ] >5), while sleep quality was significantly associated with  HRQoL (23). 
In dupi[INVESTIGATOR_902850], around 60% of patients had sleep disturbances based on the number 
of nocturnal awakenings and the nighttime symptoms reported at baseline . 
Dupi[INVESTIGATOR_902869], 
especially in patients with uncontrolled asthma and evidence of Type [ADDRESS_1266310] the IL -4Rα subunit, a component of IL -4 receptors 
Type I and Type II. The IL -4 receptors mediate the IL -4 signaling (both Type I and Type II) and 
IL-13 signaling ( Type II). Both IL -[ADDRESS_1266311] demonstrated significant improvements, 
with treatment compared to placebo in some  sleep  outcome s, such as nocturnal awakenings or 
nighttime symptoms.  
VV-CLIN-0587271 2.0Page 25

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 25 There are several subjective measures  to assess sleep quality and disturbances, however the 
majority  of them are not specific to patients with asthma (ie , PSQI ) or are n ot completely 
dedicated to assessing  sleep (ie , ACQ, Asthma Control Test [ ACT ], AQLQ) . 
Food and Drug Administration ( FDA )-validated questionnaire to assess asthma symptoms  at night  
includes the ADSD, which evaluates the impa ct of nighttime symptoms due to asthma.  
Actigraphy is one of the most common objective measures of sleep disturbances. It is a procedure 
that records and integrates the occurrence and degree of limb movement activity over time. In 
addition to providing a g raphical summary of wakefulness and sleep patterns over time, 
actigraphy generates estimates of certain sleep parameters (24). 
2.3 BENEFIT/RISK ASSESSM ENT  
Dupi[INVESTIGATOR_208434] 2 -driven immunologi cal 
disorders such as AD, bronchial asthma, chronic rhinosinusitis with nasal polyps ( CRSwNP ), and 
eosinophilic esophagitis ( EoE). A satisfactory safety profile has been observed so far in completed 
and currently ongoing studies.  
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of dupi[INVESTIGATOR_207900]’s Brochure.  
This study aims at evaluat ing the effect of dupi[INVESTIGATOR_902870], using a combination of participant -reported outcomes and objective measures  of sleep 
quality  (actigraphy) in patients with moderate -to-severe asthma and high disease burden. The 
study is medically  and scientifically justified.  
The selected dose regimen has been evaluated in dupi[INVESTIGATOR_902871] (loading dose of 400 mg 
of dupi[INVESTIGATOR_12458] [2 x 200 mg dupi[INVESTIGATOR_125347] ] on Day 1, followed by 20 0 mg Q2W ) and approved by 
[CONTACT_12721], demonstrating a positive benefit/risk.  
2.3.1  Risk assessment   
No tissue targets or specific hazards to humans were identified in noncli nical general and 
reproductive toxicology studies.  
Dupi[INVESTIGATOR_209368].  
As of 28 March 202 2 (data cut -off date), approximately 13  577 subjects were enrolled into the 
development program for dupi[INVESTIGATOR_125348]: 564 as healthy 
volunteers; 4998 from AD studies (including atopic hand and foot dermatitis); 4195 from asthma 
studies; 880 from the rhinosinusitis (CRSwNP, CRSsNP, and AFRS) studies; 468 from EoE 
studies; 275 from the allergy (grass and peanut) ; 1495 from COPD studies; 309 from PN studies; 
311 from the urticaria studies (CSU and CICU); 45 from the BP study; and 37 from the ABPA 
study.  
VV-CLIN-0587271 2.0Page 26
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 26 Based on the available sales figures and World Health Organization defined daily dose of 21.4 mg 
for parenteral formulations, the cumulative patient exposure in marketed experience could be 
estimated to be 706 212 patient years from 01 March 2017 through 31 March 2022, including 
332 123 patient years during the interval period from 01 April 2021 through 31 March 202 2.  
Dupi[INVESTIGATOR_902872] a positive benefit/risk profile . The adverse drug reactions (ADR s) 
identified to date for dupi[INVESTIGATOR_125349], conjunctivitis (including allergic 
and bacterial) , oral herpes, herpes simplex, blepharitis, dry eye, eye pruritus,  keratitis, ulcerative 
keratitis,  eosinophilia , anaphylactic reaction, angioedema , serum sickness  and arthralgia . These 
ADRs were not consistently observed in all indications (see Investigator’s Brochure [IB ] for 
greater details) . More significant serious allergic reactions were ve ry rare. Importantly, no 
increased overall infection risk was observed in patients treated with dupi[INVESTIGATOR_12458].  
Systemic hypersensitivity has been established as an important identified risk with dupi[INVESTIGATOR_12458]. As 
protein therapeutics, all monoclonal antibodies ar e potentially immunogenic. Rare serious and 
systemic hypersensitivity reactions have been observed in the dupi[INVESTIGATOR_209375]/serum sickness -like reaction in the adult AD program and anaphylaxis related to 
dupi[INVESTIGATOR_902873].  
An important potential risk for dupi[INVESTIGATOR_24783] “eosinophilia associated with clinical symptoms in 
asthma patients”.  The observed increase in eosinophil count is transient, which is consistent with 
the current understanding of the mechani sm of action of dupi[INVESTIGATOR_12458]. In dupi[INVESTIGATOR_125352], 
a small number of patients with asthma experienced serious systemic eosinophilia presenting with 
clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic 
granulomatosis w ith polyangiitis, conditions which are often treated with systemic corticosteroid 
therapy. These events have been seen in other drug development programs for severe asthma and 
usually, but not always, have been associated with the reduction of OCS  therapy suggesting 
possible unmasking of these conditions with tapering of corticosteroids during dupi[INVESTIGATOR_81228]. 
The association of dupi[INVESTIGATOR_125353]. Health care 
providers should be alert to eosinophilia associated with vasculitic rash, worsening of pulmonary 
symptoms, pulmonary infiltrate, cardiac complications, and/or neuropathy presenting in their 
patients, especially upon reduction of systemic corticosteroids.  
Patients with known helminth infections were excluded  from participation in clinical studies, 
therefore it is not known if dupi[INVESTIGATOR_718345]. Consequently, patients with pre -existing helminth infections should be treated for their 
helminth infection befo re initiating therapy with dupi[INVESTIGATOR_12458].  
Other potential risks based on the safety profile in particular indications are discussed in the IB. It 
is anticipated that dupi[INVESTIGATOR_902874] a favorable 
safety profile  as observed across other Type  2-driven immunological disorders.  
VV-CLIN-0587271 2.0Page 27
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 27 2.3.2  Benefit assessment   
Dupi[INVESTIGATOR_245574]:  
• In over 60 countries worldwide for asthma indication, including the US, for use as an add -
on maintenance treatment of adults and pediatric patients aged 6 years and older with 
moderate -severe asthma characterized by [CONTACT_902909]; the EU as an add -on maintenance treatment for adult and adolescent 
(12 years and older) patients as well as in children 6 to 11 years old with severe asthma 
with type 2 inflammation characterized by [CONTACT_24978]/or raised FeNO 
who are inadequately controlled appropriate combination therapy (high -dose ICS over 
12 years or age, medium -to-high dose in those younger, taken by [CONTACT_12699]) plus another 
medicinal product for maintenance treatment, and in Japan, for use in adults and 
adolescents (aged ≥12 years) with severe or refractory bronchial asthma . 
• In over 60 countries worldwide, including the US, EU, and Japan for the treatment of 
adults with inadequately controlled moderate -to-severe AD. In over 50 countries, 
including the US and EU, it has also been authorize d for use in adolescent patients 
(≥12  years) with inadequately controlled moderate -to-severe AD. Additionally, dupi[INVESTIGATOR_902875] 50 countries for the treatment of inadequately controlled 
pediatric patients (age 6 -11 years) with moderate t o severe AD or of pediatric patients with 
severe AD who are candidates for systemic therapy. In the US, dupi[INVESTIGATOR_902876] 6 months to 5 years of age . 
• Dupi[INVESTIGATOR_902877] 50 countries worldwide; 
including the US for the use as an add -on maintenance treatment for adults with 
inadequately controlled CRSwNP; in EU for use as an add -on therapy with intranasal 
corticosteroids (INCs) in adults with severe CRSwNP for whom therapy wit h systemic 
corticosteroids (SCSs) and/or surgery do not provide adequate disease control and in 
Japan, for use in adults with CRSwNP (only patients not adequately controlled with 
existing therapi[INVESTIGATOR_014]) . 
One of the asthma treatment goals is to eliminate asthma  symptoms at night and decrease 
awakenings due to asthma symptoms, which could lead to improved quality of life  (12). 
Dupi[INVESTIGATOR_902878], especially in patient with uncontrolled asthma and 
evidence of Type [ADDRESS_1266312] of dupi[INVESTIGATOR_902879], leading to 
better asthma control and overall improved quality of life.  
The participants with moderate -severe asthma uncontrolled by [CONTACT_902910] a 
second controller +/- a third controller might benefit by [CONTACT_902911][INVESTIGATOR_12458]  
(double -blind, randomized 1:1  study). The asthma background therapy with ICS and a second 
controller  (eg, LABA  or LTRA)  +/- a third  controller  will be maintained at a st able dose during 
the treatment period. The participants will be closely followed -up according to SoA  (Section  1.3). 
VV-CLIN-0587271 2.0Page 28
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 28 2.3.3  Benefit/risk assessment related to COVID -[ADDRESS_1266313] at study level, 
all the contingency measures are described in Appendix  7 (Section  10.7). The pa rticipants  will be  
properly informed on all these options by [CONTACT_902912], as mentioned in the Informed Consent Form. Implementation of such 
mechanisms may differ country by [CONTACT_1606], depending on country regulations and local business 
continuity plans.  
Based on the aforementioned potential benefits to patients participating in LPS16677, and the 
appropriate precautions and mitigations instituted to manage any potential impact o f COVID -[ADDRESS_1266314] of and patient participation in this trial.  
2.3.4  Overall benefit: risk conclusion   
Taking into account the measures taken to minimize risk to participants participating in this study, 
the potential risks identified in association with dupi[INVESTIGATOR_902880].  
VV-CLIN-0587271 2.0Page 29
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 29 3 OBJECTIVES AND ENDPO INTS   
Table  1 - Objectives and endpoints   
Objectives  Endpoints  
Primary  
• To assess the effect  of dupi[INVESTIGATOR_902852]  • Change from baseline to Week 12 in sleep disturbance  score  
using the  Asthma Sleep Disturbance Questionnaire  
Secondary  
• To evaluate the effect of dupi[INVESTIGATOR_902853]  • Change from baseline to Week 12 on the number of nocturnal 
awakenings (Sleep Diary)  
• Change from baseline to Week 12 in Patient -Reported 
Outcomes Measurement Information System (PROMIS) Sleep-
Related Impairment 8a scale  
• Change from baseline to Week 12 in sleep quality  (Sleep Diary)  
• Change from baseline to Week 12 in restorative sleep  (Sleep 
Diary)  
• Change from baseline to Week 12 in wake after sleep onset 
(WASO)  (Sleep Diar y) 
• To evaluate the effect of dupi[INVESTIGATOR_902854]  • Change from baseline to Week 12 in WASO based on actigraphy 
data 
• To evaluate the effect of dupi[INVESTIGATOR_902855]  • Change from baseline to Week 12 in Asthma Daytime Symptom 
Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD)  
• To evaluate the effect of dupi[INVESTIGATOR_902856]  • Change from baseline to Week 12 in prebronchodilator forced 
expi[INVESTIGATOR_12194] (pre -BD FEV 1) 
• To evaluate the safety of dupi[INVESTIGATOR_12458]  • Incidence of treatment -emergent adverse events (TEAEs) and 
serious adverse events (SAEs) including clinically significant 
changes in vital signs  
• Incidence of adverse events of special interest (AESI)  
Tertiary/exploratory  
  
 
   
 
  
 
  
 
  
   
 
  
  
  
 
  
 
 
VV-CLIN-0587271 2.0Page 30

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 32 Science37 Metasite: A virtual site (Metasite) will enroll approximately 10 participants from th e 
US. The Metasite will be managed by [CONTACT_902897]37, using telemedicine (TM), mobile study nurses, 
and an electronic application (Science37 Platform). These [ADDRESS_1266315] with their study doctors by [CONTACT_2329] a 
telemedicine (TM) model during the study. The goal of TM is to decrease the participants’ burden 
to take part in the study. The p articipants enrolled by [CONTACT_902897] 37 Metasite will not participate in 
. Further details can be found in Section  10.7. 
Randomization will be stratified according to 5 strata: one stratum for all participants included in 
the  (regardless of dose level of ICS, regardless of region)  and 4 strata for  
participants not included in , according to region and ICS dose (Eastern Europe with 
high ICS dose, Eastern Europe with medium ICS dose, ROW with high ICS dose, and ROW with 
medium ICS dose). In total, no less than 40% participants need to be in “high ICS ” strata, and no 
more than 25% participants need to be in ‘Eastern Europe’ strata.  
4.[ADDRESS_1266316] 
common objective measures of sleep disturbance  (24), clinical outcomes ( pre-BD FEV 1), 
   
The randomized double -blind treatment period of [ADDRESS_1266317] assessment 
of the efficacy and safety of dupi[INVESTIGATOR_12458]. The participants will be appropriately informed of and 
will provide written consent to the eventuality of receiving placebo during the randomized 
double -blind treatment period. They may withdraw from the study intervention or from the study 
at any time and receive the conventional treatment as prescribed by [CONTACT_099].  
VV-CLIN-0587271 2.0Page 33

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 33 The safety follow -up period will be up to 12 weeks or until the participant  switches to biologics  
(including commercialized dupi[INVESTIGATOR_12458]) , considering that after the last steady -state dose, the 
median time for dupi[INVESTIGATOR_902881], 
estimated by [CONTACT_902913] 9 weeks for the  200 mg Q2W (see the Investigator ’s 
Brochure).  
4.2.1  Participant input into design   
Not applicable.  
4.3 JUSTIFICATION FOR DOSE   
The dose regimen of SC dupi[INVESTIGATOR_125358] 200 mg Q2W. Participant s will 
receive  an initial loading dose of 400 mg (2 x 200 mg) dupi[INVESTIGATOR_125359] 1, and Q2W dosi ng will  
commence [ADDRESS_1266318].  
The results from the Phase 2b dos e ranging study (DRI12544)  (25) showed that [ADDRESS_1266319] of the eff icacy  
endpoints. Both doses were safe and well tolerated with a profile comparable to that seen with  
placebo except for an increased number of injection site reactions. To further characterize the  
optimal regimen for patients, both regimens were assessed i n the Phase  3 study ( )  (15), 
which confirmed the findings from previous studies, showing comparable efficacy and safety  
profile in both 200 mg Q2W and 300 mg Q2W dose regimens, with an overall positive  
benefit -risk profile for dupi[INVESTIGATOR_328667].  
As evidenced by [CONTACT_24983][INVESTIGATOR_12458]’s clinical development program, c linical efficacy and safety  data for 
the 200 mg dose is similar to 300  mg, however selecting 300 mg dose would imply potential 
inclusion of OCS depe ndent patients , in alignment with approved regulatory labels in some  
countries.  Patients on OCS treatment commonly experience sleep disturbances as AEs  (26), 
therefore OCS use can be a confounding variable in the evaluation of sleep outcomes , given that 
improvements in sleep outcomes could be seen due to OCS reduction or complete withdrawal that 
patients experience on dupi[INVESTIGATOR_24736]. This supports the selection of the [ADDRESS_1266320]  completed the study if he/she has completed all phases of the 
study including the post treatment follow -up visit (V6).  
The end of the study is defined as the date of the last visit of the last participant in the study.  
VV-CLIN-0587271 2.0Page 34

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 34 5 STUDY POPULATION   
Selection criteria are in line with the approved indication and refer to labeling information. 
Contraindications, precautions of use and warnings were considered.  
Prospective approval of protocol d eviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1 INCLUSION CRITERIA   
Participants are eligible to be included in t he study only if all of the following criteria apply:  
Age 
I 01. Participant must be 18 to 65 years of age inclusive, at the time of signing the informed 
consent.  
Type of participant and disease characteristics  
I 02. Participants with a physician diagnosis of asthma based on the Global Initiative for 
Asthma ( GINA ) 2020 (27) for ≥12  months treated with medium to high dose ICS and a 
second controller (ie, LABA, LTRA). A third controller is allowed but not mandatory . The 
dose regimen should be stable for at le ast [ADDRESS_1266321] hma, or treatment with systemic steroids  (oral or 
injectable) . 
I 04. Participants with e osinophils ≥150 cells/μL a nd FeNO ≥25 ppb during screening,  prior to 
randomization.  
NOTE S:  
- Historical values of blood eosinophil count meeting the eligibility criterion measured 
within 6 months prior to SV1 in the absence of OCS treatment are allowed.  
- FeNO value to be checked for eligibility at V2 as well.  
I 05. ACQ -5 ≥2.5 at SV1 and Visit 2, prior to  randomization . 
I 06. Pre-BD FEV1 ≤80% of predicted normal during screening  and at V 2, prior to 
randomization . 
I 07. Exhibit bronchodilator reversibility (≥12% and [ADDRESS_1266322] SABA 
administration) during screening  period , prior to randomization, unless reversibility test 
meeting the inclusion criteria was done within 6 month s prior to SV1. 
VV-CLIN-0587271 2.0Page 35
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 35 I 08. Weekly average nocturnal  awakening s due to asthma symptoms in the week prior to SV1 
is ≥1 . 
I 09. Willing and able to comply with all clinic visits and study -related procedures . 
Sex 
I 10. Male or female . 
Contraceptive use by [CONTACT_902914] r egulations r egarding the 
methods of contraception for those participating in clinical studies.  
a) Female participants  
- A female participant is eligible to participate if she is not pregnant or breastfeeding, 
and at least 1 of the following conditio ns applies:  
- Is not a WOCBP .  
OR 
- Is a WOCBP and agrees to use a contraceptive method  that is highly effective, with 
a failure rate of <1%, as described in Appendix  4 (Section  10.4) of the protocol 
during the study , ie, at a minimum until [ADDRESS_1266323] dose of study 
intervention  or until the participant switch es to commercialized dupi[INVESTIGATOR_12458] (or 
other biologic product), wh ichever comes first . 
- A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as 
required by [CONTACT_427]) on Day [ADDRESS_1266324] on Day 1 cannot be confirmed as negative (eg, an ambiguous result), a 
serum pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.  
- Additional requirements for pregnancy testing during and after study intervention are 
located in  Appendix  2 (Section  10.2). 
- The Investigator is responsible for review of medical history, menstrual history, and 
recent sexual activity to decrease the risk for inclusion of a woman with an early 
undetected pregnancy.  
Informed  Consent  
I 11. Capable of giving signed informed consent as described in Appendix  1 (Section  10.1.3 ) 
which includes compliance with the requirements and restrictions listed in the ICF and in 
this protocol.  In countries where l egal age of majority is above [ADDRESS_1266325] also b e signed by [CONTACT_2299]’s l egally authorized representative.  
VV-CLIN-0587271 2.0Page 36
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 36 5.2 EXCLUSION CRITERIA   
Participants are excluded from the study if any of the following criteria apply:  
Medical conditions  
E 01.  Current smoker . 
E 02.  Former smoker for 10 years with a smoking history  of >10 pack -years . 
E 03.  Severe asthma exacerbation during screening, prior to randomization . 
E 04.  History or clinical evidence of COPD  including Asthma -COPD Overlap Syndrome 
(ACOS ) or any other significant lung disease (eg, lung fibrosis, sarcoidosis, interstitial 
lung disease, pulmonary hypertension, bronchiectasis, Churg -Strauss Syndrome).  
E 05.  History of or current evidence of cl inically significant non -respi[INVESTIGATOR_3748] 
(eg, cardiovascular,  hepatic, nervous system, gastrointestinal, endocrinological, 
rheumatological, dermatological), that in the opi[INVESTIGATOR_902882].  
E 06.  Participant s with active TB  or non -tuberculous mycobacterial infection, or a history of 
incompletely treated TB will be excluded from the study unless it is well documented by a 
specialist that the participant has been adequately treated and can now start treatment with 
a biologic agent, in the medical judgment of the Investigator and/or infectious disease 
specialist. Tuberculosis testing would be  performed on a country -by-country basis , 
according to local guidelines if required by [CONTACT_902915] . 
E 07.  Diagnosed active endoparasitic infection; suspected or high risk of endoparasitic infection, 
unless clinical and (if necessary) laboratory assessment have ruled out active infection 
before randomization.  
E 08.  History of HIV  infection or positive HIV 1/2 serology at SV1 . 
E 09.  Active chronic or acute infection requiring treatment wi th systemic antibiotics, antivirals, 
antiprotozoals, or antifungals within 2 weeks before SV1.  
E 10.  Known or suspected immunodeficiency, including history of invasive opportunistic 
infections (eg, TB, histoplasmosis, listeriosis, coccidioidomycosis, pneumocysto sis, and 
aspergillosis) despi[INVESTIGATOR_12468], or otherwise recurrent infections of abnormal 
frequency or prolonged duration suggesting an immune -compromised status, as judged by 
[CONTACT_737].  
E 11.  Current evidence of clinically significant oncologic al disease, which in the opi[INVESTIGATOR_902883]. 
VV-CLIN-0587271 2.0Page 37
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 37 E 12.  History of systemic hypersensitivity or anaphylaxis to any biologic therapy  (including 
dupi[INVESTIGATOR_902884]; see Section  10.9 ). 
E 13.  Participant with severe uncontrolled depression . 
E 14.  Sleep disturbances not related to asthma, including sleep apnea, hypersomnia, or insomnia 
secondary to chronic pain, AD, COPD , etc, as determined by [CONTACT_737] . 
E 15.  Participant s who work night shifts (ie, any work between 8 PM and 6 AM). 
E 16.  Participant s with erratic sleep habits, as determined by [CONTACT_737] . 
E 17.  Evidence of restless leg syndrome or periodic limb movement disorder . 
Prior/concomitant therapy  
E 18.  Chronic treatment with OCS within 2 weeks prior to SV1. 
E 19.  Participant s taking sedative , anxiolytic , or hypnotic treatments , including  melatonin , 
within 3  months before randomization . 
E 20.  Participant s taking systemic sedative antihistamines (this does not include the newer 
generation s of antihistamines)  or theophylline .  
E 21.  Current treatment with antidepressant s, lipophilic beta blockers, clonidine, opi[INVESTIGATOR_2438], or 
other medications known to interfere with sleep and may confound the study assessments, 
as determined by [CONTACT_737].  
Note: In most cases, chronic treatments administered regularly and at stable dos ing should 
be acceptable. Investigators should assess the degree to which an individual medication 
may cause changes in sleep pattern or sleep quality during the study, compared to the pre -
baseline state.  
E 22.  Participant  who has taken biologic therapy  (includi ng dupi[INVESTIGATOR_12458]) /systemic 
immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid 
arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus 
erythematosus, multiple sclerosis, etc) within 2  months or 5 half -lives before SV1, 
whichever is longer.  
E 23.  Treatment with live (attenuated) vaccine within 4 weeks before SV1. 
NOTE: For participants who have vaccination with live, attenuated vaccines planned 
during the course of the study (based on national vaccination sche dule/local guidelines), it 
will be determined, after consultation with a physician, whether the administration of 
vaccine can be postponed until after the end of the study  (ie, after the [ADDRESS_1266326]) , or preponed to before the start of the study 
without compromising the health of the participant:  
VV-CLIN-0587271 2.0Page 38
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 38 - Participant  for whom administration of live (attenuated) vaccine can be safely 
postponed would be eligible to enroll into the study.  
- Participant s who have their vaccination preponed can enroll in the study only after a 
gap of 4  weeks following administration of the v accine.  
E 24.  Planned or anticipated use of any prohibited medications ( Section  6.5) and procedures 
during screening and stu dy treatment period.  
Prior/concurrent clinical study experience  
E 25.  Enrolled in other ongoing studies regardless of the investigational product.  
E 26.  Treatment with an investigational drug within 1 month  or within 5 half -lives (if known), 
whichever is longer, prio r to SV1. 
Diagnostic assessments  
E 27.  Participant s with any of the following results at SV1:  
• Positive (or indeterminate) HBsAg  or, 
• Positive total HBcAb confirmed by [CONTACT_125447],  
• Positive HCVAb  confirmed by [CONTACT_125448].  
Other exclusions  
E 28.  Individuals accommodated in an institution because of regulatory or legal order; prisoners 
or participants who are legally institutionaliz ed. 
E 29.  Participant not suitable for participation, whatever the reason, as judged by [CONTACT_3786], including medical or clinical conditions, or participants potentially at risk of 
noncompliance to study procedures . 
E 30.  Participants are employees of the clinic al study site or other individuals directly involved 
in the conduct of the study, or immediate family members of such individuals  (in 
conjunction with section 1.61 of the ICH -GCP Ordinance E6) . 
E 31.  Any specific situation during study implementation/course that may rise ethics 
considerations . 
E 32.  Sensitivity to any of the stud y interventions, or components thereof, or drug or other 
allergy that, in the opi[INVESTIGATOR_689], contraindicates participation in the study .  
5.3 LIFESTYLE CONSIDERATIONS   
No restrictions are required.  
VV-CLIN-0587271 2.0Page 39
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 39 5.4 SCREEN FAILURES   
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomly assig ned to study intervention . A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT ) publishing requirements and to respond 
to queries from r egulatory authorities. Minimal information includes demography, screen failure  
reasons , eligibility criteria, and any SAE.  
Reasons for screen failure may be unfulf illed eligibility criteria and withdrawal of consent during 
screening period, between screening and randomization.  
Participant s who do not meet the eligibility criteria for participation in this study and for whom 
resolution of the screen failure reason ma y not be expected within a reasonable time frame will be 
deemed a screen failure.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened.  The participant s may be rescreened once during the open screenin g period . There is 
no requirement for a waiting period between the screen failure date and the rescreening date. 
Participant s who are rescreened must sign a new consent form and all SV1 procedures must be 
repeated. A different participant  identification number will be issued.  The interactive voice 
recognition system  (IVRS )/ interactive web response system ( IWRS ) report will flag rescreened 
participant s.  
If certain dynamic laboratory tests do not meet the eligibility criteria, these laboratory assessments 
may be repeated, at the discretion of the Investigator, if it is judged that they are likely to return  to 
acceptable range for study inclusion within the screening visit window prior to Day  1. These 
participant s do not need to sign a new ICF and a new participant  number will not be allocated.  
Retesting of eosinophil values is allowed up to 3 times during t he screening period to meet 
inclusion criteria for showing eosinophil count ≥ 150 cells/µL ( I 04) before randomization.  This is 
only required if the participant  doesn’t have the blood eosinophils measured within [ADDRESS_1266327] meeting the 
eligibility criterion was not performed within 6 months prior to SV1.  
FeNO can be assessed one additional time during the screening if the FeNO value measured at 
SV1 doesn’t meet the eligibility criterion.  
VV-CLIN-0587271 2.0Page 40
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 40 5.5 CRITERIA FOR TEMPORA RILY DELAYING SCREENING, RANDOMIZA TION, OR 
STUDY INTERVENTION  ADMINISTRATION   
During  a regional or national emergency declared by a governmental agency, if the site is unable 
to adequately follow protocol mandated procedures, contingency measures  proposed in 
Appendix  8 (Section  10.8) should be considered for the screening, randomization, or 
administration of study intervention . 
VV-CLIN-0587271 2.0Page 41
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 41 6 STUDY INTERVENTION   
Study intervention  is defined as any investigational intervention (s), marketed product(s), placebo, 
or medical device(s) intended to be administered to a study parti cipant according to the study 
protocol.  
6.1 STUDY INTERVENTION (S) ADMINISTERED   
Table  2 - Overview of study intervention s administered   
ARM name [CONTACT_125502][INVESTIGATOR_12458] 200 mg  Placebo  
Intervention name [CONTACT_125502][INVESTIGATOR_12458]  200 mg Placebo matching dupi[INVESTIGATOR_12458] 200  mg 
Type  Biological  Other  
Dose formulation  Dupi[INVESTIGATOR_12458] 200  mg: a  175 mg/mL 
dupi[INVESTIGATOR_125314] a prefilled syringe 
to deliver 200  mg in 1.14  mL Placebo matching dupi[INVESTIGATOR_12458] 200  mg 
will be supplied as an  identical 
formulation to the active 200  mg 
formulation without dupi[INVESTIGATOR_12458], in a 
prefilled syringe t o deliver placebo in 
1.14 mL 
Unit dose strength(s)  200 mg  0 mg  
Dosage level(s)  200 mg every 14 ±3 days after an initial 
loading dose of 400  mg 0 mg every 14 ±3 days after an initial 
loading dose of 0  mg  
Route of administration  SC injectiona SC injectiona 
Use experimental  placebo - comparator  
IMP and NIMP  IMP IMP 
Packaging and labeling  One glass prefilled syringe packed in a 
participant  kit box. Both glass prefilled 
syringe and box will be labeled as 
required per country requirement.  One glass prefilled syringe packed in a 
participant  kit box. Both glass prefilled 
syringe and box will be labeled as 
required per country requirement.  
Current/Former name(s) or 
alias(es)  Dupi[INVESTIGATOR_12460]   
a SC injection sites should alternate between the upper thighs, 4 quadrants of the abdomen or the upper arms, so that the same sit e is not 
injected twice during consecutive administrations. Injection in the upper arms can only be done by a trained person (care giver) trained by 
[CONTACT_207999]) or health care professional but not the participants themselves.  
IMP: investigational medicinal product; SC: subcutaneous . 
In specific situation, between the protocol -scheduled on -site visits, interim visits may be required 
for IMP dispensing. As an alternative to the on -site IMP dispensing , IMP may be supplied from 
the site to the participant via a Sponsor -approved courier company where allowed by l ocal 
regulations and approved by [CONTACT_2299] . 
For participants enrolled through virtual site (Metasite), IMP will be supplied from the virtual site 
to the participant via DTP service which will be handled and under the responsibility of 
Science37 . For a regional or national emergency declared by a governmental agency that results 
in travel restrictions, confinement, or restricted site access, contingency measures are included in 
Appendix  8 (Section  10.8). 
VV-CLIN-0587271 2.0Page 42
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 42 The Investigator or delegate will train the participant (or caregiver) how to prepare and inject IMP 
at Visit 2. The site staff will inject the first dose of the  two injections. The partici pant (or 
caregiver) will perform the second injection under the supervision of the Investigator or delegate. 
This training must be documented in the participant’s study file. At subsequent administrations , 
participants are allowed to self -inject IMP at hom e.  
For participants enrolled through Science37 Metasite, IMP will be administered by a mobile study 
nurse at the randomization dosing visit. As described above, the participants /caregivers will be 
instructed how to prepare and self -inject/inject the IMP a t the first dosing visit and will be allowed 
to self -administer /administer  for the remainder of the treatment period. If the participant is not 
comfortable with self -administration, the mobile study nurse will perform the administrations at 
home visits at every 2  weeks , according to the scheduled IMP administrations. The mobile study 
nursing management with all related activities will be under the responsibility of Science37 . 
Participants should be instructed to avoid missing any dose of medication during t he study. Any 
participant who misses one dose should be reminded to be diligent, in order to avoid further 
missing doses thereafter. In case of missed dose(s), no loading dose of  two injections will be 
administered when restarting the treatment, whatever t he number of missed doses. The 
participant s should continue their scheduled IMP treatment and visits, even if more than  two 
consecutive doses were missed.  
When the participant has a study visit, the IMP will be administered following clinical procedures 
and blood collection. Participant s should be monitored for at least 30 minutes. The monitoring 
period may be extended as per country -specific or local site -specific requirements.  
If the participant (or caregiver) is unable or unwilling to administer IMP, injections can be 
performed at the site by [CONTACT_181252]; or arrangements can be made for qualified site 
personnel and/or health care professional s (eg,  visiting nurse service) to administer IMP for the 
doses that are not scheduled to be given at the study site  or if the participant can’t attend the on -
site visit .  
Subcutaneous injection sites should alternate between the upper thighs, 4 quadrants o f the 
abdomen or the upper arms, so that the same site is not injected twice during consecutive 
administrations. Injection in the upper arms can only be done by a trained person (caregiver or 
delegate) or health care professional but not the participants t hemselves.  
Participant or caregiver should be trained by [CONTACT_902916] -monitor/monitor at home for at least 
30 minutes (or longer per country -specific or local site -specific requirements) following injection. 
In case of hypersensitivity symptoms , the participant  should contact [CONTACT_147204]/emergency.  
A home dosing diary  will be provided to  collect information related to at home injections. The 
diary will be kept  as source data in the participant ’s study file.  
VV-CLIN-0587271 2.0Page 43
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266328](s)  
Participants  should be on a stable dose of medium to high dose ICS in combination with a 
second  controller medication (eg, LABA, LTRA) ≥1 month prior to SV1 and during the Screening 
Period ( Table  3).  
Participants requiring a third controller for their asthma will be considered eligible for this study, 
also at a stable dose ≥1 month prior to SV1 and during the Screening Period.  Theophyll ine is not 
allowed knowing that it can interfere with sleep and may confound the study assessments.  
• Formulation and route(s) of administration: refer to label.  
• Dose regimen: as prescribed.  
The asthma background therapy should be maintained on a stable dose  during the study treatment 
period.  
Short -acting β2 agonists may be used as rescue medication during the study if needed.  
Systemic corticosteroids are allowed for the treatment of severe  asthma exacerbations.  
Table  3 - Medium and hi gh daily doses of inhaled corticosteroids (mcg)   
Inhaled corticosteroid  Medium  High  
Beclometasone dipropi[INVESTIGATOR_16847] ( pMDIa, HFA ) >500 -1000  >1000  
Beclometasone dipropi[INVESTIGATOR_16847] ( pMDI, extrafine particle, HFA ) >200 -400 >400  
Budesonide (DPI)  >400 -800 >800  
Ciclesonide ( pMDI, extrafine particle, HFA)  >160 -320 >320  
Fluticasone furoate (DPI)  100. 200 
Fluticasone propi[INVESTIGATOR_16847] (DPI)  >250 -500 >500  
Fluticasone propi[INVESTIGATOR_16847] ( pMDIa, HFA)  >250 -500 >500  
Mometasone furoate  (DPI)  200 440 
Mometasone furoate  (pMDIa, HFA ) 200-400 400 
DPI = Dry powder inhaler; HFA  = Hydrofluoroalkane propellant  (non-CFC), pMDI  = pressurized metered dose inhaler.  
a standard  (non-fine) particle s.  
The GINA table above refers to metered doses. This is not a table of equivalence  but suggested 
total daily ICS doses for the “medium ” and “high” dose options. I t is based on available studies 
and product information . Doses may be country -specific depending on  local availability, 
regulatory labelling , and clinical guidelines . For new preparations, the manufacturer’s  product 
information should be reviewed carefully, as products containing the same molecule may not be 
clinical ly equivalent ( 27). The list presents examples of ICS and might support future changes.  
An asthma background therapy diary will be provided to collect information related to 
noninvestigational medicinal product ( NIMP ) use. The diary will be kept as source data in the 
participant’s study file.  
VV-CLIN-0587271 2.0Page 44
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 44 6.1.1  Devices   
Not applicable . 
6.2 PREPARATION/HANDLING /STORAGE/ACCOUNTABIL ITY  
1. The Investigator  or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are reported 
and resol ved before use of the study intervention.  
2. Only participants enrolled in the study may receive study intervention and only authorized site 
staff may supply or administer study intervention. All study intervention must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the Investigator  and authorized site 
staff.  
3. The Investigator , institution, or the head of the medical institution (where applicabl e) is 
responsible for study intervention accountability, reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records).  
4. Science 37 Metasite: For the preparation, handling, storage and accountability of study 
intervention, refer to Appendix 7 ( Section  10.7). 
Responsibilities  
Any quality issue noticed with the receipt or use of an IMP  (deficiency in condition, appearance, 
pertaining documentation, labeling, expi[INVESTIGATOR_320], etc) must be promptly notified to the Sponsor . 
Some deficiencies may be recorded through a complaint procedure (see Section  8.3.7 ). 
A potential defect in the quality of IMP may be subject to initiation of a recall procedure by [CONTACT_429] . In this case, the Investigator  will be responsible for promptly addressing any request 
made by [CONTACT_1034] , in order to recall the IMP and eliminate potential hazards.  
Under no circumstances will the Investigator supply IMP to a third party DTP shipment, unless 
the courier company has been approved by [CONTACT_1034]  (or Science37 for the virtual site), or  
allow the IMP to be used other than as directed by [CONTACT_13129], or dispose of IMP in 
any other manner . 
6.3 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND B LINDING   
Randomization  
A randomized intervention kit number list will be generated centrally by [CONTACT_13225]. The IMP 
(dupi[INVESTIGATOR_24885]) will be packaged in accordance with this lis t.  
The [COMPANY_011] Clinical Supplies team will provide the randomized intervention kit number list and 
the Study Biostatistician will provide the randomization scheme to the centralized intervention  
allocation system. This centralized intervention allocation s ystem will generate the participant  
randomization list according to which it will allocate the intervention  to the participant s.  
VV-CLIN-0587271 2.0Page 45
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 45 The Investigator obtains intervention kit numbers at randomization (V isit 2) and subsequent 
scheduled visits via an IVRS/IWRS that will be available 24 hours a day.   
Science37  Metasite: The investigator of Metasite  obtains intervention kit numbers at 
randomization (Visit 2) and subsequent scheduled visits via IVRS/IWRS . Science37 participant 
randomization in IVRS/IWRS will occur on Day  1, with first loading dose occurring  up to [ADDRESS_1266329] randomization to account for the lag between IVRS/IWRS randomization trigger for IMP 
DTP shipment and IMP availability to participant/mobile study nurse.  
Science37 participant windows increased up to 3 days (the maximum visit window ) for the 
subsequent at home dosing visits (week 4, week 8, week 12), to account for the lag between 
IVRS/IWRS trigger for IMP DTP shipment and IMP availability to participant/mobile study 
nurse . 
Participant s who meet the entry criteria will be randomized to receive either dupi[INVESTIGATOR_125366]. Participant s will be randomized  centrally  using a 1:1 randomization ratio for dupi[INVESTIGATOR_12458] 
200 mg Q2W and placebo Q2W. Randomization will be stratified according to 5 strata: 
one stratum for all participants included in the  (regardless of dose level of ICS, 
regardless of region)  and 4 strata for participants not included in , according to 
region and ICS dose (Eastern Europe with high ICS dose, Eastern Europe with medium ICS dose, 
ROW with high ICS dose, and ROW with medium ICS dose). In total, no less than 
40% participants need to be in “high ICS ” strata, and no more than 25% participants need to be in 
“Eastern Europe ” strata.  
A randomized participant  is defin ed as a participant  who is registered and assigned with a n 
intervention  kit number from the centralized intervention  allocation system, as documented from 
its log file , regardless  whether the intervention kit was used or not . A participant  cannot be 
random ized more than once in the study.  
Returned IMP from the participant ’s home should not be re -dispensed to the participants.  
Methods of blinding  
Dupi[INVESTIGATOR_125367] 1.[ADDRESS_1266330] the blind, each intervention kit of 1.14 mL (dupi[INVESTIGATOR_12458]/placebo) glass prefilled syringes 
will be prepared such that the treatments (dupi[INVESTIGATOR_125368]) are identical and 
indistinguishable and will be labeled with a treatment kit number. The randomized  treatment kit 
number list will be generated by [CONTACT_13225].  
Both the participant  and Investigator will be blinded to assigned active drug or placebo. Study 
participant s, investigators, and study site personnel will not have access to the randomization 
(treatme nt codes).  
Randomization code breaking during the study  
In case of an AE, the code must only be broken in circumstances when knowledge of the IMP is 
required for treating the participant . 
VV-CLIN-0587271 2.0Page 46

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 46 Code breaking can be performed at any time by [CONTACT_208537]/IWRS 
and/or by [CONTACT_125459]. If the blind is 
broken, the Investigator must document the date, time of day, and reason for code breaking.  
Participant  withdrawal will only occur when t he code break call is made at the site level, not the 
study level. This means that if the Emergency Unblinding transaction is performed by [CONTACT_3786] (ie, at the site level), then the participant  will be withdrawn from treatment. However, 
if the Emer gency Unblinding transaction is performed by [CONTACT_125460] (ie, at the 
study level, as the Global Safety Officer is not site based), then the participant  will not be 
withdrawn from treatment.  
Participant s who are withdrawn from treatment should  be encouraged to remain in the study and 
the Investigator should discuss with them the key visits to attend (see Section  7.1). 
6.4 STUDY INTERVENTION  COMPLIANCE   
Measures taken to ensure and document intervention compliance and IMP accountability include:  
• Proper recording of intervention kit number as required on appropriate electronic case 
report form (e -CRF)  page for accounting purposes.  
• All intervention kits (whether empty or unused) are returned by [CONTACT_902917] a n intervention dispensing is planned:  
• Science37  Metasite: All intervention kits accountability and return (whether empty or 
unused) will be managed and under the responsibility of Science37 . 
- The completed participant  home dosing  diary (returned to the site  at each visit), 
returned intervention kits and any unused prefilled syringes will be used for drug 
accountability purposes.  
• The Investigator  or designee tracks intervention accountability/compliance, either by 
[CONTACT_155668], or by [CONTACT_902918].  
The monitor in charge of the study then checks the data entered on the IMP administration page 
by [CONTACT_902919].  
The Investigator, pharmacist, or qualified nurse  will also keep accurate records of the quantities of 
the IMP received, dispensed, used, unused, and returned/destroyed. The product accountability 
and inventory form/system are to be updat ed each time IMP is dispensed.  
All used, partially used, or unused interventions will be destroyed at each respective site, after 
accountability and reconciliation have been performed. The site must not destroy the unused IMP 
unless the Sponsor provides wr itten authorization. Confirmation of destruction will be provided to 
the Sponsor.  
VV-CLIN-0587271 2.0Page 47
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 47 6.5 CONCOMITANT THERAPY   
Any medication or vaccine (including over -the-counter or prescription medici nes) that the 
participant is receiving at the time of enrollment or receives during the study must be recorded 
along with:  
• Reason for use . 
• Dates of administration including start and end dates . 
• Dosage information including dose and frequency . 
During the FU  period the asthma treatment will be administered based on Investigator's medical 
judgment and normal clinical practice.  
The Medical Monitor should be contact[CONTACT_21445] r egarding concomitant or 
prior therapy.  
Prohibited concomitant thera py:  
• Any biologic therapy (including experimental treatments) or systemic immunosuppressive 
drugs . 
• Treatment with systemic corticosteroids  (systemic corticosteroids can only be used to treat 
a severe  asthma exacerbation and are not allowed to be used for o ther conditions) . 
• Treatment with live (attenuated) vaccine .  
• Sedative, anxiolytic , or hypnotic treatments including melatonin .  
• Antihistamines , except the newer generation s of antihistamines  (eg, cetirizine, loratadine 
and fexofenadine) . 
• Theoph ylline. 
• Lipophilic beta blockers, opi[INVESTIGATOR_2438], clonidine, antidepressants or other  medications known 
to interfere with sleep, as determined by [CONTACT_32366] . 
Note: In most cases, chronic treatments administered regularly and at stable dosing are acceptable. 
Invest igators should assess the degree to which an individual medication may cause changes in 
sleep pattern or sleep quality during the study, compared to the prebaseline state.  
6.5.1  Rescue medicine   
The SABA rescue medications may be used. The rescue medication will be administered as 
prescribed by [CONTACT_099].  Systemic corticosteroids are allowed for the treatment of severe 
asthma exacerbations.  
Although the use of rescue medications is a llowed at any time during the study, every attempt 
should be made to perform all necessary measurements prior to the use of rescue medications. If 
SABA rescue medications are given prior to  or spi[INVESTIGATOR_038], the measurements should be 
performed after a wash -out time mentioned in Table  4 (Section  8.1.3 ). The date and time of rescue 
medication administration as well as the name [CONTACT_902951] . 
VV-CLIN-0587271 2.0Page 48

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 48 6.6 DOSE MODIFICATION   
Not applicable.  
6.7 INTERVENTION  AFTER THE END OF TH E STUDY   
No intervention is planned after the end of the study.  
VV-CLIN-0587271 2.0Page 49
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 49 7 DISCONTINUATION  OF STUDY INTERVENTI ON AND 
PARTICIPANT DISCONTI NUATION/ WITHDRAWAL   
Withdrawal of consent for treatment (ie, treatment discontinuation at participant  request) should 
be distinguished from (additional) withdrawal of consent for follow -up visits. The site should 
document any case of withdrawal of consent.  
7.1 DISCONTINUATION OF S TUDY INTERVENTION   
7.1.1  Definitive  discontinuation   
In rare instances, it may be necessary for a participant to permanently discontinue  (definitive 
discontinuation)  study intervention. If stud y intervention is definitively discontinued, the 
participant will remain in the study to be evaluated for  efficacy and safety . See the S oA 
(Section  1.3) for data to be collected at the time of discontinuation of study intervention  and 
follow -up and for any further evaluations that need to be completed.  
Discontinuation of study intervention  for abnormal liver function should be considered by [CONTACT_184146] a participant meets one of the conditions outlined in the algorithm “Increase in 
ALT ” (Section  10.5) or if the Investigator  believes that it is in be st interest of the participant.  
List of criteria for permanent discontinuation of study intervention  
Every effort should be made to document t he reason(s) for discontinuation of study intervention  
and this should be documented in the e -CRF.  
Participant s may be withdrawn from the study intervention for the following reasons:  
• At their own request or at the request of their legally authorized repre sentative (legally 
authorized representative means an individual or judicial or other body authorized under 
applicable law to consent on behalf of a prospective participant  to the participant 's 
participation in the procedure(s) involved in the research).  
• If, in the Investigator's opi[INVESTIGATOR_1649], continuation in the study would be detrimental to the 
participant’s  well-being.  
• At the specific request of the Sponsor.  
• If the Emergency Unblinding transaction is performed by [CONTACT_737] (ie, at the site 
level).  
• Pregnancy.  
• Anaphylactic reactions or systemic allergic reactions that are related to IMP and require 
treatment  (see Section  10.9). 
• Diagnosis of a malignancy during study, excluding carcinoma in situ of the cervix, or 
squamous or basal cell carcinoma of the skin.  
VV-CLIN-0587271 2.0Page 50
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 50 • Any opportunistic infection, such as tuberculosis or other infections whose nature or 
course may suggest an i mmunocompromised status.  
• Serum ALT >3 upper limit of normal (ULN ) and Total Bilirubin > [ADDRESS_1266331] (see 
Section  10.5, Appendix 5).  
• Serum ALT >[ADDRESS_1266332] if baseline ALT ≤[ADDRESS_1266333] or ALT >[ADDRESS_1266334] if baseline ALT  >[ADDRESS_1266335] 
(see Section  10.5, Appendix 5).  “Baseline” refers to ALT sampled at baseline visit or, if 
baseline value is unavailable, to the latest ALT value before the baseline visit.  
See the SoA ( Section  1.3) for data to be collected at the time of intervention discontinuation and 
follow -up and for any further evaluations that need to be completed.  
Any abnormal laboratory value will be immediately rechecked  for confirmation before making a 
decision of definitive discontinuation of the IMP for the concerned participant.  
Handling of participants after definitive intervention  discontinuation  
Participant s will be followed -up according to the study procedures specified in this protocol up to 
the scheduled date of EOT visit (V isit 5), or up to recovery or stabilization of any AE to be 
followed -up as specified in this protocol, whichever comes last.  
Particip ants who prematurely discontinue the study intervention (prior to completing the 12-week 
treatment period) should attend an ETD visit at earliest convenience with all procedures required 
at the EOT visit, except IMP. In particular cases when the ETD visit is closed to a regular study 
visit, ETD could be merged and will replace the regular visit. In addition, the participant s will be 
asked and encouraged to complete all the remaining study visits according to the visit schedule 
until and including the EOT vi sit (V isit 5). Participant s will be followed -up according to the study 
procedures specified in this protocol in SoA ( Section  1.3). Under exceptional circumstances when 
a participant  cannot come to the site for the scheduled visit, a phone contact [CONTACT_902920]. During the phone contact, at  least information about AEs and 
concomitant medication should be collected.  
All cases of permanent discontinuation of study intervention should be recorded by [CONTACT_125466] e -CRF when considered as confirmed.  
7.1.2  Temporary discontinuation   
Temporary intervention  discontinuation may be considered by [CONTACT_902921] a regional or nat ional emergency declared 
by a governmental agency . For a regional or national emergency declared by a governmental 
agency, contingency measures are included in Appendix 8 (Section  10.8). For all temporary 
intervention  discontinuations, duration should be recorded by [CONTACT_902922] e -CRF.  
The following definition can be considered:  temporary intervention  discontinuation decided by 
[CONTACT_902923] . 
VV-CLIN-0587271 2.0Page 51
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 51 In addition, the following conditions will be causes for temporary discontinuation of study 
intervention:  
• Infections o r infestations that do not respond to medical treatment . 
• Treatment with a live (attenuated) vaccine . 
• Treatment with immunomodulating biologics  (including experimental treatments) . 
• Treatment with systemic corticosteroids  (except systemic corticosteroids used to treat a 
severe asthma exacerbation)  or systemic immunosuppressive drugs . 
• Any laboratory abnormality that meets temporary treatment discontinuation criteria as per 
Appendix 5 ( Sectio n 10.5). 
[IP_ADDRESS]  Rechallenge   
Reinitiation of intervention  with the IMP will be done under close and appropriate clinical/and or 
laboratory monitoring once the Investigator  will have considered according to his/her best medical 
judgment that the responsibility of the IMP(s) in the occurrence of the concerned even t was 
unlikely and if the selection criteria for the study are still met ( Section  5.1 and Section  5.2). 
For a regional or national emergency declared by a governmental agency, contingency measures 
are included in  Appendix 8 (Section  10.8). 
7.2 PARTICIPANT DISCONTI NUATION/ WITHDRAWAL FROM THE STUDY   
• A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the Investigator  for safety, behavioral, 
compl iance, or administrative reasons.  This is expected to be uncommon.  
• A participant  who prematurely discontinue s the study should attend an ESD visit at the 
earliest convenience with all the procedures planned for the End of Treatment Visit 
(Visit  5) except I MP, as shown in the SoA ( Section  1.3). See SoA for data to be collected 
at the time of study discontinuation and f ollow -up and for any further evaluations that 
need to be completed.  
• The participant will be permanently discontinued both from the study intervention and 
from the study at that time.  
• If the participant withdraws consent for disclosure of future informatio n, the Sponsor  may 
retain and continue to use any data collected before such a withdrawal of consent.  
If participants no longer wish to take the IMP, they will be encouraged to remain in the study.  
The Investigator s should discuss with them key visits to attend. The value of all their study data 
collected during their continued involvement will be emphasized as important to the public health 
value of the study.  
VV-CLIN-0587271 2.0Page 52
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266336] be 
documented.  
All study withdrawals should be recorded by [CONTACT_686590] 
e-CRF and in the participant’s medical records. In the medical rec ord, at least the date of the 
withdrawal and the reason should be documented.  
In addition, a participant may withdraw his/her consent to stop participating in the study. 
Withdrawal of consent for intervention  should be distinguished from withdrawal of cons ent for 
follow -up visits and from withdrawal of consent for non -participant contact [CONTACT_6492] -up, 
eg, medical record checks. The site should document any case of withdrawal of consent.  
Participants who have withdrawn from the study cannot be rerandomized/real located (treated) in 
the study. Their inclusion and intervention  numbers must not be reused.  
7.[ADDRESS_1266337] be taken if a participant fails to return to the clinic for a required study 
visit:  
• The site must attempt to contact [CONTACT_21455]/or should continue in 
the study.  
• Before a participant is  deemed lost to follow -up, the Investigator  or designee must make 
every effort to r egain contact [CONTACT_6635] (where possible, 3 telephone calls and, if 
necessary, a certified letter to the participant’s last known mailing address or local 
equivale nt methods). These contact [CONTACT_13140]’s 
medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1  
(Section  10.1.8 ). 
VV-CLIN-0587271 2.0Page 53
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 53 8 STUDY ASSESSMENTS AN D PROCEDURES   
• Study procedures and their timing are summarized in the SoA  (Section  1.3). Protocol 
waivers or exemptions are not allowed.  
• Adherence to the study design requirements, including those specified i n the SoA, is 
essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator  will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management (eg, blood 
eosin ophil count , reversibility test ) and obtained before signing of the ICF may be utilized 
for screening or baseline purposes provided the procedures met the protocol -specified 
criteria and were performed within the time frame defined in the SoA.  
• The lab orato ry tests will be done locally , the maximum amount of blood collected from 
each participant over the duration of the study will be according to the routine clinical 
practice in each country and site. As the blood analysis will be performed by [CONTACT_902924], any leftover  blood sample will not be used for any other research purposes 
related to the study (re -analyses) or for future exploratory use (secondary use) . Repeat or 
unscheduled samples may be taken for safety reasons or for technical issues wit h the samples .  
• Patient -reported outcome measures  completed at the clinical site  should be completed by 
[CONTACT_2299] s before the consultation and/or clinical tests, in a quiet place  when 
completed at study visits . The questionnaires  should be completed by [CONTACT_2299] s 
themselves, independently from their physician, the  study nurse or any other medical 
personnel and without any help from friends or relatives.  
• Science37 Metasite: For the study procedures performed by [CONTACT_2299] s enrolled by 
[CONTACT_902925] , refer to Appendix  7 (Section  10.7) 
For a regional or national emergency declared by a g overnmental agency, contingency measures 
are included in  Appendix  8 (Section  10.8). 
8.[ADDRESS_1266338] or 
ankle. Mathematical  algorithms are then applied to these data to esti mate wakefulness and sleep. 
In addition to providing a graphical summary of wakefulness and sleep patterns over time, 
actigraphy generates estimates of certain sleep parameters  (24). 
VV-CLIN-0587271 2.0Page 54
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 55 For prebronchodilator measured parameters, including FEV 1 and forced vital capacity ( FVC ), 
spi[INVESTIGATOR_902885]:  
Table  4 - Wash -out period of asthma controllers and rescue medication before and lung 
function assessments   
Oral Xanthine derivatives  
Long -acting beta agonists (LABA) (eg , salmeterol)  [ADDRESS_1266339] (LAMA) ( eg, Tiotropi[INVESTIGATOR_1890])  48 hours  
Inhaled ICS/LABA  24 hours  
Inhaled Ultralong ICS/LABA combinations  48 hours  
Inhaled and/or nebulized SABAs ( eg, salbutamol)  6 hours  
Inhaled and/or nebulized SAMAs ( eg, ipratropi[INVESTIGATOR_1890])  8 hours  
SABA/SAMA combination  8 hours  
Inhaled and/or nebulized corticosteroids (ICS)  12 hours  
Systemic corticosteroids (oral, IM, IV)  4 weeks  
ICS: inhaled corticosteroid; IM : intramuscular;  IV: intravenous; LABA: long -acting beta agonist; LAMA : long-acting muscarinic antagonist ; 
SABA : short -acting beta [ADDRESS_1266340] ; SAMA : short -acting muscarinic antagonist   
This will be verified before performing the measurements.  
For post -bronchodilator FEV 1, the measurement should follow the steps as that at screenin g test 
for reversibility validation.  
At all visits, spi[INVESTIGATOR_125372], in the morning, if 
possible. The spi[INVESTIGATOR_902886], including calibr ation, will be used to perform spi[INVESTIGATOR_125374], whenever 
possible, the same person should perform the measurements . Afternoon/evening is allowable in 
the exceptional circumstance when morning spi[INVESTIGATOR_125375] . Spi[INVESTIGATOR_902887].  
Pulmonary function tests will be measured in the sitting position if possible. If  the testing was 
made  with the participant  in another position, this should be noted on the spi[INVESTIGATOR_125377]. For 
any participant , the position should be consistent throughout the study.  
Three measurements fulfilling the ATS acceptability and repeatability criteria should be obtained 
at each visit. The acceptability criteria must be applied before the repeatability criteria. 
Unacceptable maneuvers must be discarded before applying the repeatability criteria. If a 
participant  fails to provide repeatable maneuvers, an explanation should be recorded  in the e -CRF. 
At least  two acceptable curves must be obtained.  
The largest FEV [ADDRESS_1266341] been examined , even if they do not come from the same curve.  
VV-CLIN-0587271 2.0Page 56

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266342] be c alibrated following the principles of the ATS/ERS guidelines every day 
that a participant  is seen and subjected to spi[INVESTIGATOR_038]. The calibration records should be kept in a 
reviewable log. It is preferred that the equipment that is used to calibrate the spir ometer (ie, 3 -liter 
syringe) be subjected to a validated calibration according to the manufacturer’s specifications. A 
participant  who is unable to complete a successful spi[INVESTIGATOR_902888] -BD FEV1 at SV1 can 
be retested one additional time during the screening period of the study. The spi[INVESTIGATOR_902889]. Further details on the procedure will be provided in a separate instruction manual . 
8.1.[ADDRESS_1266343] been withheld for the appropriate intervals  ment ioned in Table  4. Participant s 
will receive 2 to 4 puffs of albuterol/salbutamol from a primed metered dose inhaler (MDI ). 
Alternatively, and only if it is consistent with usual office practice (to be documented), 
reversibility may be performed using inhalation of nebulized albuterol/salbutamol. Spi[INVESTIGATOR_181202] 30  minutes after administration of bronchodilator. 
Reversibility , which is defined as an increase in absolute FEV 1 of ≥12% over the baseline value,  
with an absolute increase of at least [ADDRESS_1266344] be demonstrated within 30 minutes of 
bronchodilator administration. If the participant  does not meet the reversibility at  SV1, up to 
3 repeat attempts can be performed at any time (ie,  unscheduled visits) prior to the randomization 
visit (V isit 2). This is only required if a reversibility test meeting eligibility criterion was not 
performed within [ADDRESS_1266345] of 
asthma on participant s’ sleep. Scores range between [ADDRESS_1266346] the severity of the disturbance of their sleep due to asthma  
as follows:  
• 0 = Slept through the night, no asthma symptoms , 
• 1 = Slept well, no nighttime awakenings  because of asthma , but some asthma symptoms  in 
the morning , 
• 2 = Woke up once because of asthma ( may or may not includ e early awakening),  
• 3 = Woke up several times because of asthma ( may or may not include early awakening),  
• 4 = Bad night, awake most of the night because of asthma . 
The participants will record their sleep disturbance in an electronic diary, once a day upon 
awakening. The participants will complete Asthma Sleep Disturbance Questionnaire as per SoA 
(see Section  1.3). 
VV-CLIN-0587271 2.0Page 57
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 57 Science37 Metasite: For the completion of the  baseline and postbaseline assessments, refer to 
Appendix  7 (Section  10.7). 
8.1.6  Asthma daytime symptom diary - Asthma nighttime symptom diary   
The ADSD and ANSD are PRO  measures developed by [CONTACT_902926]’ Asthma Working 
Group. Both instruments  have been designed to measure asthma symptoms i n adult and 
adolescent (12 years of age and older) participant s diagnosed with mild to severe asthma. ADSD  
and ANSD assess asthma severity based on patient self -report of asthma core symptoms, ie , 
difficulty breathing; wheezing; shortness of breath; chest tightness; chest pain; and cough . 
Participant s are asked to complete the ADSD every night before they go to bed, thinking about 
their asthma symptoms today, from when they got up this morning until now; the ANSD when 
getting up, thinking about their asthma  symptoms last night from when they went to bed until 
now.  
They have demonstrated adequate evidence of content validity and cross -sectional measurement 
properties (ie, internal consistency reliability, test -retest reliability, convergent validity, and 
know n-groups validity) to measure symptoms of asthma. Both the ADSD and ANSD are 
composed of 6 items rated using an 11 -point NRS that ranges from 0 = None to 10 = As bad as 
you can imagine (29).  
The participants will complete the ADSD  and the ANSD as per SoA (see Section  1.3). 
Science37 Metasite: For the completion of the baseline and postbaseline assessments, refer to 
Appendix 7 ( Section  10.7). 
8.1.7  Sleep diary  
The Sleep Diary  is composed of seven generic, patient -reported questions that assess sleep 
concepts of relevance and importance to adults who report sleep disturbance due to asthma.  
The Sleep Diary  features two subjective, patient -rated items that use a 0 -to-10 NRS to assess sleep 
quality and feeling rested upon awakening (ie, restorative sleep). Additional  items include the 
patient -estimated initial sleep attempt time and sleep onset time, number of nighttime awakenings 
after sleep onset, total time spent awake after sleep onset, and wake time the next day. Participant s 
are instructed to complete all questi ons upon awakening each day. All questions except the one 
about restorative sleep a sk participant s to recall “last nigh t”; question about restorative sleep asks 
participant s to recall “when they got up for  the day today ”. Items about sleep quality and 
restorative sleep are scored; the other items are reported/described separately, as appropriate for 
each item.  
The participants will complete the items of the Sleep Diary  daily, as per SoA (see Section  1.3). 
Science37 Metasite: For the completion of the baseline and postbaseline assessments, refer to 
Appendix  7 (Section  10.7). 
VV-CLIN-0587271 2.0Page 58
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 61 8.2 SAFETY ASSESSMENTS   
Planned time points for all safety assessments are provided in the SoA  (Section  1.3). 
8.2.1  Physical examinations   
• A complete physical examination will include, at a minimum, assessments of the 
cardiovasc ular, respi[INVESTIGATOR_696], gastrointestinal and neurological  systems. Height and weight 
will also be measured and recorded.  Height (cm) will be measured only at SV1. 
• Investigator s should pay special attention to clinical signs related to previous serious 
illnesses . 
• Any new finding or worsening of previous finding should be reported as a new AE. 
8.2.2  Vital signs   
• Temperature (degrees Celsius), heart rate (beats per minute), respi[INVESTIGATOR_697] (breaths per 
minute), and blood pressure (mmHg) will be assessed.  
• Blood pressure and pulse measurements will be assessed with a completely automated 
device. Manual techniques will be used only if an automated device is not available.  
• Blood pressure and pul se measurements should be preceded by [CONTACT_2669] [ADDRESS_1266347] 
for the participant in a quiet setting without distractions ( eg, television, cell phones)  and 
will consist of 1 pulse and 3 blood pressure measurements ([ADDRESS_1266348] 1 minute). The average of the 3 blood 
pressure readings will be recorded in the e-CRF.  
8.2.3  Electrocardiograms   
• 12-lead ECG will be obtained at SV1 as outlined in the SoA  (see Section  1.3) using an 
ECG machine that automatically calculates the heart rate an d measures PR, QRS, QT  
intervals.  
8.2.4  Clinical safety laboratory assessments   
• See Appendix  2 (Section  10.2) for the list of clinical laboratory tests to be performed and  
the SoA  (Section  1.3) for the timing and frequency.  
• The laboratory tests will be performed by [CONTACT_902927].  Considering this, any leftover blood sample will 
not be us ed for any other research purposes related to the study (re -analyses) or for future 
exploratory use (secondary use).  
• The Investigator  must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF. The 
laboratory reports must be filed with the source documents. Clinically significant 
abnormal la boratory findings are those which are not associated with the underlying 
disease, unless judged by [CONTACT_209485] ’s condition.  
VV-CLIN-0587271 2.0Page 62
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 62 • All laboratory tests with values considered clinically significantly abnorm al during 
participation in the study  should be repeated until the values return to normal or baseline 
or are no longer considered clinically significant by [CONTACT_184156].  
- If such values do not return to normal/baseline within a period  of time judged 
reasonable by [CONTACT_737] , the etiology should be identified,  and the Sponsor  
notified.  
- All protocol -required laboratory assessments, as defined in  Appendix  2 (Section  10.2), 
must be conducted in accordance with the SoA (Section  1.3).  
- If laboratory values from non -protocol specified laboratory assessments performed at 
the institution’s local laboratory require a change in participant management or are 
considered clinica lly significant by [CONTACT_737]  (eg, SAE or AE or dose 
modification), then the results must be recorded in the e-CRF.   
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENT S  
Adverse  events  will be reported by [CONTACT_2299] (or, when appropriate, by a car egiver, 
surrogate, or the participant ’s legally authorized representative).  
The Investigator  and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that 
caused the participant to discontinue the  study intervention  (see Section  7).  
8.3.1  Time period and frequency for collecting AE and SAE information   
All SAEs will be collected from the signing of the  ICF until the EOS  Visit  (Visit 6) at the time 
points specified in the SoA ( Section  1.3). 
All AE s will be collected from the signing of the ICF  until the EOS Visit (Visit 6) at the time 
points specified in the SoA  (Section  1.3). 
All SAEs and AESI will be recorded and reported to the Sponsor  or designee  immediately and 
under no circumstance should this exceed  24 hours, as indicated in  Appendix  3 (Section  10.3). 
The Investigator  will submit any updated SAE data to the Sponsor  within 24  hours of it being 
available.  
Investigator s are not obligated to actively seek AE or SAE after conclusion of the study 
participation . However, if the Investigator  learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention or study participation, the Investigator  must promptly notify the 
Sponsor . 
VV-CLIN-0587271 2.0Page 63
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 63 8.3.2  Method of detecting AEs and SAEs   
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 ( Section  10.3). 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
8.3.3  Follow -up of AEs and SAEs   
After the initial AE/ AESI/ SAE report, the Investigator  is required to proactively follow each 
participant at subsequent v isits/contacts. At the  prespecified study end -date, a ll SAEs,  and AE SI 
as defined in Section  8.3.6 ), will be followed until resolution, stabilization, the event is otherwise 
explained, or the participant is lost to follow -up (as defined in Section  7.3). Further information 
on follow -up procedures is provided in Appendix  3 (Section  10.3). 
8.3.4  Regulatory reporting requirements for SAEs   
• Prompt notification by [CONTACT_208022] a SAE is essential so that l egal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
a study intervention under clinical investigation are met.  
• The Sponsor  has a l egal responsibility to notify both t he local r egulatory authority and 
other r egulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor  will comply with country -specific r egulatory requirements 
relating to safety reporting to the r egulatory authority, Institutional Review Boards 
(IRB )/Independent Ethics Committees (IEC ), and Investigator s. 
• Adverse events that a re considered expected will be specified in the reference safety 
information ( the IB and its updates ).  
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs .) according to local regulatory requirements and Sponsor policy and 
forwarded to Investigators as necessary.  
• An Investigator who receives an Investigator safety report describing a SAE, S[LOCATION_003]R or 
any other specific safety  information ( eg, summary or listing of SAEs) from the Sponsor 
will review and then file it along with the Investigator’s Brochure and will notify the 
IRB/IEC, if appropriate according to local requirements.  It is the responsibility of the 
Sponsor to assess w hether an event meets the criteria for a S[LOCATION_003]R, and therefore, is 
expedited to regulatory authorities.  
8.3.5  Pregnancy   
• The pregnanc y information for  female participants or female partners of male participants  
will be collected after the start of study intervention and until the outcome has been 
determined . Generally, the follow -up will be no longer than 6 to 8 weeks following the 
estimated delivery date.  
VV-CLIN-0587271 2.0Page 64
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 64 • If a pr egnancy is r eported, the Investigator  should inform the Sponsor  within 24 hours of 
learning of the pr egnancy and should follow the procedures outlined in  Appendix  4 
(Section  10.4). 
• Abnormal pr egnancy outcomes ( eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pr egnancy) are considered SAEs.  
• The participant /pregnant female partner will be followed to determine the outcome of the 
pregnancy. The Investigator will collect follow -up information on the participant /pregnant 
female partner and the neonate,  and the information will be forwarded to t he Sponsor.    
• Any post -study pregnancy -related SAE considered reasonably related to the study 
intervention by [CONTACT_78795]. While the Investigator is 
not obligated to actively seek this information in former study partic ipants /pregnant 
female partner, he or she may learn of an SAE through spontaneous reporting.  
• Any female participant who becomes pregnant while participating in the study will 
discontinue the study intervention.  
8.3.[ADDRESS_1266349]   
An AESI  is an AE (serious or nonserious) of scientific and medical concern specific to the 
Sponsor’s product or program, f or which ongoing monitoring and immediate notification by [CONTACT_21470]. Such events may require further investigation in order to 
characterize and understand them. Adverse events of special interest may be added, modified or 
removed during a study by [CONTACT_12548].  
For these AESIs, the Sponsor will be informed immediately (ie, within 24 hours), per SAE 
notification described in Section  10.3.4 , even if not fulfilling a seriousness criterion, using the 
screens in the e -CRF.  
• Anaphylactic reactions  (see Section  10.9). 
• Systemic hypersensitivity reactions . 
• Helminthic infections . 
• Keratitis . 
• Any severe type of conjunctivitis or blepharitis . 
• Clinically symptomatic  eosinophilia (or eosinophilia associated with clinical symptoms) . 
• Significant ALT elevation  
- ALT >5 × the ULN in participants with baseline ALT ≤2 × ULN; “Baseline” refers to 
ALT sampled at baseline visit or, if baseline value is unavailable, to the lates t ALT 
value before the baseline visit , 
or  
- ALT >8 × ULN if baseline ALT >2 × ULN.  
• Pregnancy of a female participant entered in a study as well as pregnancy occurring in a 
female partner of a male participant entered in a study with IMP .  
VV-CLIN-0587271 2.0Page 65
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 65 - Pregnancy occurrin g in a female participant entered in the clinical trial or in a female 
partner of a male participant entered in the clinical trial. It will be qualified as an SAE 
only if it fulfills one of the seriousness criteria (see Appendix 3 [ Section  10.3]). 
- In the event of pregnancy in a female participant, IMP should be discontinued.  
- Follow -up of the pregnancy in a female par ticipant or in a female partner of a male 
participant is mandatory until the outcome has been determined (See Appendix 4 
[Section  10.4]) 
• Symptomatic overdose (serious or nonserious) with IMP/NIMP  
- An overdose (accidental or intentional) with the IMP is an event suspected by [CONTACT_902928] 11 days. The circumstances 
(ie, accidental or intentional) should be clearly specified in the verbatim and 
symptoms, if any, entered on separate adverse event forms.  
- An overdose (accidental or intentional) with any NIMP is an event suspected by [CONTACT_902929], within the intended therapeutic interval . 
8.3.[ADDRESS_1266350] complaint form within required timelines.  
Appr opriate information ( eg, samples, labels or documents like pi[INVESTIGATOR_12989]) related to 
product identification and to the potential deficiencies may need to be gathered. The Investigator  
will assess whether or not the quality issue has to be reporte d together with an AE or SAE.  
8.[ADDRESS_1266351] twice the intended dose during an interval of less 
than 11 days. Symptomatic overdose (serious or nonserious)  is an AESI (defined in Section  8.3.6 ). 
No antidote is available for dupi[INVESTIGATOR_12458] . 
In the event of an overdose, the Investigator should:  
1. Contact [CONTACT_27465] . 
2. Closely monitor the participant for any AE/SAE and labo ratory abnormalities until 
dupi[INVESTIGATOR_718369].  
3. Obtain a plasma sample for pharmacokinetic analysis as soon as possible from the date of 
the last dose of study intervention if requested by [CONTACT_1689] (determined on a 
case-by-case basis).  
4. Document appropriately in the e -CRF.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_633491].  
VV-CLIN-0587271 2.0Page 66
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266352] to those research projects.  
Data will be used in compliance with the information provided to participants in the ICF Part 2 
(future research).  
All study participant data will be coded suc h that no participant direct identifiers will be linked to 
them. Coded data may be transferred to a Sponsor site (or a subcontractor site), which may be 
located outside of the country where the study is conducted. The Sponsor adopts safeguards for 
protecti ng participant confidentiality and personal data (see Section  10.1.4 ). 
Study participant coded data will be stored fo r future research for up to 25 years after the end of 
the study. If data are still considered of important scientific value after this period, coded data 
already available will be anonymized unless otherwise required by [CONTACT_5751].  
Participant’s coded  data sets provided to researchers for a specific research project will be 
available to the researchers for a maximum of  two years after the end of their specific project (end 
of project is defined by [CONTACT_902930] e research project 
report).  
VV-CLIN-0587271 2.0Page 68
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 69 9.3 POPULATIONS FOR ANAL YSES   
The following populations are defined ( Table  5): 
Table  [ADDRESS_1266353] of all participant s with a treatment kit number allocated and recorded in 
the IVRS database, regardless of whether the treatment kit was used or not.  
Participant s treated without being randomized will not be considered as randomized and will not be 
included in any efficacy population. Data from these participant s will be summarized separately.  
ITT The analysis population for the efficacy endpoints  (except the pri mary endpoint)  will be the intent -to-
treat population: all randomized participant s will be included in the ITT population and  analyzed 
according to the treatment group allocated by [CONTACT_17628].  
ITT for primary 
endpoint (ITTp ) All ITT participants excluding those who used the original version of sleep disturbance questionnaire at 
baseline and/or post -baseline. This analysis population is only applied to p rimary endpoint analysis.  
Safety (As -treated)  All randomized participants who take at least 1 dose of study intervention will be the safety population. 
Participants will be analyzed according to the intervention they actually received.  Randomized 
particip ants for whom it is unclear whether the study medication  or intervention  was taken will be 
included in the safety population as randomized. For participants receiving more than one IMP during 
the study (i.e., placebo and dupi[INVESTIGATOR_12458]), the actual study intervention group for as treated analysis will 
be the dupi[INVESTIGATOR_24769].  
ITT: intent -to-treat; ITTp: intent -to-treat for primary endpoint; IVRS: interactive voice recognition system  
9.4 STATISTICAL ANALYSES   
The statistical analysis plan  (SAP ) will be developed and finalized prior to  database lock  and it 
will include a more technical and detailed description of the statistical analyses described in this 
section.  This section is a summary of the  planned  statistical analyses of the  most important 
endpoints  including primary and key secondary endpoints.  
9.4.[ADDRESS_1266354] available value before randomization.  
The primary analysis will be performed on  the ITTp population, and all other efficacy analyses 
will be performed on the ITT population, unless otherwise noted. All safety analyses will be 
performed on the Safety Population.  
VV-CLIN-0587271 2.0Page 70
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 70 9.4.2  Primary endpoint (s)  
The primary endpoint is change from baseline  in sleep disturbance  score at Week [ADDRESS_1266355] square (LS) mean of each treatment group, 
difference in the LS mean between the dupi[INVESTIGATOR_125316], and the corresponding 
95% CI of the differences and p -values will be provided. For participants discontinuing the study 
intervention before Week [ADDRESS_1266356], for any 
participants discontinuing the study intervention due to the COVID -19 pandemic, off -study 
intervention data will not be included (i.e., s et to missing) but will be assumed missing at random . 
The sensitivity analysis will be conducted using the ITT population.  
9.4.3  Secondary endpoint(s)   
Differences  will be assessed  between dupi[INVESTIGATOR_902890]:  
• Change from baseline to Week  12 on the number of nocturnal awakenings ( Sleep Diary ). 
• Change from baseline to Week  12 in prebronchodilator FEV1 . 
• Change from baseline to Week  12 in ADSD and ANSD . 
• Change from baseline to Week  12 in PROMIS Sleep -Related Impairment  8a scale . 
• Change from baseline to Week  12 in Sleep Diary Questions : sleep quality, restorative 
sleep, and WASO . 
• Change from baseline to Week 12 in WASO from actigraphy  data.  
The change from baseline in the above continuous endpoints to Week 12 will  be analyzed using 
the MMRM model in the same fashion as for the primary endpoint , based on the ITT population .  
For the spi[INVESTIGATOR_270942], the model will also include sex and baseline height as the 
covariates.  
The details for the analysis for actigraphy will be provided in the SAP.  
The incidence of TEAEs, SAEs including clinically significant changes in vital signs, and AESI 
will be used to evaluate the safety of dupi[INVESTIGATOR_12458] . 
VV-CLIN-0587271 2.0Page 71
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 72 9.5 INTERIM ANALYSES   
An interim analysis ( IA) in the study is planned for the purpose of  when 
approximately 50% of participants  (approximately 130 participants  from the ITTp population ) 
would have completed Week  12 visit  or discontinued the study . The sample size re -estimation is 
planned to mitigate  risk of power loss , given the large variability of placebo effects  observed in 
 Interim analysis will be performed as follows:  
• The sample size re -estimation will be performed based on the observed treatment effects at 
the time of IA. Sample size may  be increased if conditional power falls into the promising 
zone. No additional IA will be performed in the case of sample size increase. The test 
statistic at the final analysis may be adjusted as appropriate and details will be specified in 
the SAP.  
• Ther e is no plan to stop trial early for superiority at the time of IA. In order to preserve the 
overall Type  I error rate of 0.05 (2 -sided), gamma family alpha spending function will be 
utilized.   
The IA will be performed by [CONTACT_902931] l team, who are separate from 
personnel involved in the trial conduct. An independent Interim Analysis Committee (IAC ) 
consisting of  two clinicians and one statistician will review the results a nd make decision if the 
sample size need s to be adjusted based on prespecified criteria . A detailed plan will be defined in 
the SAP, including the plan to describe the processes intended to control access to comparative 
interim results to preserve trial in tegrity. People involved in the conduct of the study ( participant s, 
Investigators, Study Team, and Project Team) will have no access to the IA results.  
At the  time of  IA, the primary efficacy endpoint will be analyzed using the same method 
described in the primary endpoint section ( Section  9.4.2 ). The analysis population for the IA will 
be approximately  [ADDRESS_1266357] participant  
completes the Week 12 visit or discontinues from the study before Week 12. Analyses will be 
based on all data collected up to this database lock and will be considered as the f inal analysis in 
the CSR.  
VV-CLIN-0587271 2.0Page 73

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 73 10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS   
10.1 APPENDIX 1:  REGULATORY, ETHICAL, AN D STUDY OVERSIGHT 
CONSIDERATIONS   
10.1.1  Regulatory and ethical considerations   
• This study will be conducted in accordance with the protocol and with the following:  
- Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and the applicable amendments and Council for International 
Organizations of Medical Sciences (CIOMS ) International Ethical Guidelines . 
- Applicable International Council for Harmonisation ( ICH) Good Clinical Practice 
(GCP) Guidelines . 
- Applicable laws and r egulations  (eg, data protection law as General Data Pro tection 
Regulation - GDPR ). 
• The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents ( eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_902932]/IEC before the study is initiated.   
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate  
hazard to study participants.   
• The Investigator  will be responsible for the following:  
- Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
establis hed by [CONTACT_1201]/IEC  Determining whether an incidental finding should be 
returned to a participant and, if it meets the appropriate criteria, to ensure the finding is 
returned  (an incidental finding is a previously undiagnosed medical condition that is 
discovered unintentionally and is unrelated to the aims of the study for which the tests 
are being performed) . The following should be considered when determining the return 
of an incidental finding:  
- The return of such information to the study participant (and/or his/her designated 
healthcare professional, if so designated by [CONTACT_2299]) is consistent with all 
applicable national, state, or regional laws and regulations in th e country where the 
study is being conducted, and  
- The finding reveals a substantial risk of a serious health condition or has 
reproductive  importance, AND has analytical validity, AND has clinical validity .  
- The participant in a clinical study has the righ t to opt out of being notified by [CONTACT_21481]. In the event that the participant has opted 
out of being notified and the finding has consequences for other individuals, eg, the 
VV-CLIN-0587271 2.0Page 74
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266358] in the 
site medical files that she/he does not want to know about such findings.  
- Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures . 
- Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR ), ICH guidelines, the IRB/IEC, 
European r egulation 536/2014  for clinical studies (if applicable), and all other 
applicable local r egulations . 
As applicable, according to Directive 2001/20/EC, the Sponsor will be responsible for obtain ing 
approval from the Competent Authorities of the EU Member States and /or Ethics Committees, as 
appropriate, for any amendments to the clinical trial  that are deemed as “substantial” ( ie, changes 
which are likely to have a significant impact on the safety or physical or mental integrity of the 
clinical trial participants or on the scientific value of the trial) prior to their implementation.  
10.1.2  Financial disclosure   
Investigator s and sub -Investigator s will provide the Sponsor  with sufficient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or dis closure statements to the appropriate r egulatory authorities. Investigator s are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study . 
10.1.3  Informed consent process   
• The Investigator  or his/her representative will explain the nature of the study to the 
participant or his/her l egally authorized representative and answer all questions r egarding 
the study , including what happens to the participant when his/her participation ends 
(posttrial access strategy for the study) .  
• Participants must be informed that their participation is voluntary. Participants or their 
legally authorized representative will be requir ed to sign a statement of informed consent 
that meets the requirements of [ADDRESS_1266359] (HIPAA ) requirements, where applicable, 
and the IRB/IEC or study center.  
• Science37 Metasite participants will complete the consent process remotely  with 
Science37 study staff and sign the eConsent in the  Science37  platform, accessible via an 
App on a smartphone or tablet, or on a computer desktop browser . 
• The medical record must incl ude a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.  
VV-CLIN-0587271 2.0Page 75
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 75 • In case of ICF amendment  while the participants are still included in the study, they must 
be re -consented to the most current version of the ICF(s).  Where participants are not in the 
study anymore, teams in charge of the amendment must define if those participants must 
or not re -consent or be informed of the amendment (eg, if the processing of personal data 
is modified, if the Sponsor changes, etc) .  
• A copy of the ICF(s) must be provided to the participant or the participant’s l egally 
authorized representative.  
• Science37 Metasit e participants will be informed that they may download and print a copy 
of the eICF, or a copy may be emailed to them upon the participant’s request.  
• Participants who are rescreened are required to sign a new ICF.  
The ICF contains  two separate sections tha t addresses the use for research of participants’ data. 
Optional exploratory research must be detailed in the section “Optional tests/procedures” and 
future research is to be defined in Core Study Informed Consent Form  (CSICF ) Part 2. Each 
option is subject to an independent consent and must be confirmed by [CONTACT_13158] a checkbox in 
CSICF Part 3. The Investigator or authorized designee will explain to each participant the 
objectives of the expl oratory research and why data are important for future research. Participants 
will be told that they are free to refuse to participate and may withdraw their consent at any time 
and for any reason during the storage period.  
For a regional or national emerg ency declared by a governmental agency, contingency measures 
are included in  Appendix 8 (Section  10.8).  
10.1.4  Data protection   
All personal data collected and/or processed in relation to this study will be handled in 
comp liance with all applicable Privacy & Data Protection laws and regulations, including the 
GDPR. The study Sponsor is the [COMPANY_011] company responsible for ensuring compliance with this 
matter, when processing data from any individual who may be included in the  [COMPANY_011] databases, 
including Investigators, nurses, experts, service providers, Ethics Committee members, etc.  
When archiving or processing personal data pertaining to the Investigator and/or to the 
participants, the Sponsor takes all appropriate measures  to safeguard and prevent access to this 
data by [CONTACT_13159].  
Protection of participant data  
Data collected must be adequate, relevant and not excessive, in relation to the purposes for which 
they are collected. Each category of data must be properly justified and in line with the study 
objective.  
Participant race and ethnicity will be collected in this study because they are expected to modify 
the drug response/because they are required by [CONTACT_17513] (eg, on African American 
popul ation for the FDA or on Japanese population for the Pharmaceuticals and Medical Devices 
Agency in Japan)”. They will not be collected in the countries where this is prohibited by [CONTACT_21482].  
VV-CLIN-0587271 2.0Page 76
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 76 • Participants will be assigned a unique identifier by [CONTACT_10577]. Any participant records or 
datasets that are transferred to the Sponsor or its service providers will be identifiable only 
by [CONTACT_13160]; participant names or any information which would make the 
participant identifiable will not be trans ferred to the Sponsor.  
• The participant must be informed that his/her personal study -related data will be used by 
[CONTACT_13161]. The level of disclosure 
must also be explained to the participant as described in the informed consent .  
• The participant must be informed that his/her medical records may be examined by 
[CONTACT_13162], by [CONTACT_6667]/IEC members, and by [CONTACT_6668].  
• Participants must be informed that their study -related data will be used for the whole “drug 
development program”, ie, for this trial as well as for the following steps necessary for the 
development of the investigational product, including to support negot iations with payers 
and publication of results.  
Protection of data related to professionals involved in the study  
• Personal data (eg, contact [CONTACT_8972], affiliation(s) details, job title and related professional 
information, role in the study, professional resume, training records) are necessary to 
allow [COMPANY_011] to manage involvement in the study and/or the related contractual or pre -
contractual relationship. They may be communicated to any company of the [COMPANY_011] group 
(“[COMPANY_011]”) or to [COMPANY_011] service providers , where needed.  
• Personal data can be processed for other studies and projects. At any time, objection to 
processing can be made by [CONTACT_13164] (link available at 
[COMPANY_011].com).   
• In case of refusal to the processing of person al data by [CONTACT_13165], it will be 
impossible to involve the professionals in any [COMPANY_011] study. In case the professionals have 
already been involved in a [COMPANY_011] study, they will not be able to object to the processing of 
their personal data as l ong as they are required to be processed by [CONTACT_5279]. 
The same rule applies in case the professionals are listed on a regulatory agencies 
disqualification list.  
• Personal data can be communicated to the following recipi[INVESTIGATOR_840]:  
- Personnel within [COMPANY_011] or partners or service providers involved in the study .  
- Judicial, administrative and regulatory authorities, in order to comply with legal or 
regulatory requirements and/or to respond to specific requests or orders in the 
framework of judicial or a dministrative procedures. Contact [CONTACT_21486]  
• Personal data may be transferred towards entities located outside the Economic European 
Area, in countries w here the legislation does not necessarily offer the same level of data 
protection or in countries not recognized by [CONTACT_225404]. Those transfers are safeguarded by [CONTACT_902933], notably:  
VV-CLIN-0587271 2.0Page 77
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266360] contractual clauses of the European Commission for transfers towards 
our partners and service providers,  
- [COMPANY_011]’s Binding Corporate Rules for intra -group transfers.  
• Professionals have the possibility  to lodge a complaint with [COMPANY_011] leading Supervisory 
Authority, the “Commission Nationale de l’Informatique et des Libertés” (CNIL) or with 
any competent local regulatory authority.  
• Personal data of professionals will be retained by [CONTACT_902934] y (30) years, unless 
further retention is required by [CONTACT_5279].  
• In order to facilitate the maintenance of Investigators personal data, especially if they 
contribute to studies sponsored by [CONTACT_13170], [COMPANY_011] participate s 
in the Shared Investigator Platform (SIP) and in the Transcelerate Investigator Registry 
(IR) project (https://transceleratebiopharmainc.com/initiatives/investigator -registry/). 
Therefore, personal data will be securely shared by [CONTACT_902935]. This sharing allows Investigators to keep 
their data up -to-date once for all across pharmaceutical companies participating in the 
project, with the right to object to the transfer of the data to the Tra nscelerate project.  
• Professionals have the right to request the access to and the rectification of their personal 
data, as well as their erasure (where applicable) by [CONTACT_225405]: [COMPANY_011] DPO - 54 rue La Boétie - [ZIP_CODE] PAR IS - [LOCATION_009] (to contact [CONTACT_13173], visit https://www.sanofi.com/en/our -responsibility/sanofi -global -privacy -
policy/contact ). 
10.1.5  Dissemination of clinical study data   
Study participants  
[COMPANY_011] shares information about clinical trials and results on publicly  accessible websites, based 
on company commitments, international and local l egal and r egulatory requirements, and other 
clinical trial disclosure commitments established b y pharmaceutical industry associations. These 
websites include clinicaltrials.gov, EU clinicaltrialr egister (eu.ctr), and sanofi.com, as well as 
some national r egistries.  
In addition, results from clinical trials in participant s are required to be submitte d to peer -
reviewed journals following internal company review for accuracy, fair balance and intellectual 
property. For those journals that request sharing of the analyzable data sets that are reported in the 
publication, interested researchers are directe d to submit their request to www.vivli.org . 
Individual participant data and supporting clinical documents are available for request at 
www.vivli.org . While making information available we continue to protect the privacy of 
participants in our clinical tria ls. Details on data sharing criteria and process for requesting access 
can be found at this web address: www.vivli.org .  
VV-CLIN-0587271 2.0Page 78
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 78 Professionals involved in the study or in the drug development program  
[COMPANY_011] may publicly disclose, and communicate to relevant authorities/institutions, the funding, 
including payments and transfers of value, direct or indirect, made to healthcare organizations and 
professionals and/or any direct or indirect advantages and/or any related information or document 
if required by [CONTACT_87117], by [CONTACT_13175] a code of conduct such as the “EFPIA Code on 
Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and 
Healthcare Organisations”.  
10.1.6  Data quality assurance   
• All participant data relating to the study will be recorded on electronic CRF unless 
transmitted to the Sponsor  or designee electronically ( eg, laboratory data). The 
Investigato r is responsible for verifying that data entries are accurate and correct by 
[CONTACT_113559].  
• The Investigator  must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
• The Investigator  must permi t study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
• Monitoring details describing strat egy (eg, risk -based initiatives in operations and quality 
such as Risk Management a nd Mitigation Strat egies and Analytical Risk -Based 
Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in separate study documen ts. 
• The Sponsor  or designee is responsible for the data management of this study including 
quality checking of the data.  
• The Sponsor assumes accountability for actions del egated to other individuals 
(eg, Contract Research Organizations  [CRO ]) 
• Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the sa fety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable r egulatory requirements.  
• Records and documents, inclu ding signed ICFs, pertaining to the conduct of this study 
must be retained by [CONTACT_14344] 25 years after the signature [CONTACT_208055] r egulations or institutional policies require a longer retention period. No 
records may be destroyed during the retention period without the written approval of the 
Sponsor . No records may be transferred to another location or party without written 
notificati on to the Sponsor .  
10.1.7  Source documents   
• Source documents provide evidence for the existence of the participant and substantiate 
the int egrity of the data collected. Source documents  are filed at the Investigator ’s site.  
VV-CLIN-0587271 2.0Page 79
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 79 • Data entered in the e -CRF that are transcribed from source documents must be consistent 
with the source documents or the discrepancies must be explained. The Investigator  may 
need to request previous medical records o r transfer records, depending on the study. Also, 
current medical records must be available.  
• Definition of what constitutes source data : source data is all information in original 
records and certified copi[INVESTIGATOR_34504], obser vations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial . 
Source data are contained in source documents. Source documents are original documents, 
data and records such as hospi[INVESTIGATOR_1097], clinic and off ice charts, laboratory reports, 
notes, memoranda, pharmacy dispensing records,  home dosing diary, asthma background 
therapy diary,  recorded data from automated instruments etc. Data downloaded from the 
local laboratories, spi[INVESTIGATOR_038], actigraphy, , ECG, patient diaries , 
electronic PROs will be considered source data.  
• The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
• Study monitors will perform ongoing source data verific ation to confirm that data entered 
into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance w ith the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
• For the Science37 Metasite, the Science37 platform is the repository for all source 
documents and participant information . 
10.1.[ADDRESS_1266361] been collected and a study  site closure visit has been performed.  
The Investigator  may initiate study  site closure at any time, provided there is reasonable cause and 
sufficient noti ce is given in advance of the intended termination.  
Reasons for study termination by [CONTACT_1034], as well as reasons for the early closure of a study 
site by [CONTACT_208049]:  
• For study termination:  
- Information  on the product leads to doubt as to the benefit/risk ratio . 
- Discontinuation of further study intervention development . 
VV-CLIN-0587271 2.0Page 80

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 80 • For site termination:  
- Failure of the Investigator  to comply with the protocol, the requirements of the 
IRB/IEC or local health authoriti es, the Sponsor ’s procedures, or GCP guidelines . 
- Inadequate or no recruitment (evaluated after a reasonable amount of time) of 
participants by [CONTACT_737] . 
- Total number of participants included earlier than expected . 
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any CRO (s) used in the study of the 
reason for termination or suspension, as specified by [CONTACT_76542] e regulatory requirements. The 
Investigator shall promptly inform the participant  and should assure appropriate participant  
therapy and/or follow -up. 
10.1.9  Publication policy   
• The resul ts of this study may be published or presented at scientific meetings. If this is 
foreseen, the Investigator  agrees to submit all manuscripts or abstracts to the Sponsor  
before submission. This allows the Sponsor  to protect proprietary information and to 
provide comments.   
• The Sponsor  will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor  will generally support 
publication of multicenter studies only in their entirety and n ot as individual site data. In 
this case, a coordinating Investigator  [INVESTIGATOR_12992].  
• Authorship will be determined by [CONTACT_14346].  
10.2 APPENDIX 2: CLINICAL LA BORATORY TESTS   
• The tests detailed in Table  6 will be performed by [CONTACT_12082] .  
• Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section  5 of the protocol . 
• Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_245986] r egulations . 
• Pregnancy testing (urine or serum as required by [CONTACT_427]) should be conducted as 
mentioned in the SoA ( Section  1.3). 
• Pregnancy testing (urine or serum as required by [CONTACT_427]) should be conducted at 
the end of relevant systemic exposure corresponding with the time frame for female 
participant contraception in Section  5.1, Inclusion Criteria.  
• Additional serum or urine pregnancy tests may be performed, as determined necessary by 
[CONTACT_31837], to establish the absence of pregnancy at 
any time during the participant 's participation in the study.  
VV-CLIN-0587271 2.0Page 81
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 81 • In exceptional situations when the participants cannot attend the on -site visits, 
arrangements can be made for qualified site personnel and/or health care professionals 
(eg, visiting nurse service) for blood sample collection, if allowed by [CONTACT_902936].  
• Science37  Metasite : the blood sample collection and pregnancy tests (if applicable) will be 
done at participants’ home by [CONTACT_902937]37  home nursing service . The processing, 
shipment, analysis of the blood samples are under Science37  responsibility.   
Table  6 - Protocol -required laboratory assessments   
Laboratory assessments  Parameters  
Hematology  Eosinophils  
Other screening tests  Highly  sensitive (Serum at screening and urine at the other visits) human chorionic 
gonadotropin (hCG) pregnancy test (as needed for women of childbearing potential) .  
Hepatitis screening covering hepatitis B surface antigen (HBsAg), total hepatitis B core 
antib ody (total HBcAb); hepatitis C virus antibodies (HCVAb). In case of results showing 
HBs Ag (negative), and HBcAb (positive), an HBV DNA testing will be performed to rule out 
a false positivity if the Investigator believes the participant  is a false positiv e, or to clarify the 
serological status if the Investigator finds it unclear to interpret in absence of known HBV 
infection. In case of results showing HCVAb (positive), an HCV RNA testing may be 
performed to rule out a false positivity, if the Investigato r believes the participant  is a false 
positive.  
Human Immunodeficiency Virus screening (Anti -HIV-1 and HIV -2 antibodies).  
Tuberculosis test performed only on a country by [CONTACT_902938].  
The results of each test must be entered into the CRF.  
NOTES:  
Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments after liver stoppi[INVESTIGATOR_125402]  7.1 and Appendix  5 (Section  10.5). Although the liver function tests are not r equested in the protocol, the routinely done lab tests 
might identify increased values of ALT, bilirubin. All events related to ALT, bilirubin which may indicate severe liver injur y (possible Hy’s Law) 
must be reported as an SAE.  
Investigator s must document their review of each laboratory safety report.  
10.3 APPENDIX 3: ADVERSE EVENTS: DEFI NITIONS AND PROCEDUR ES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING   
10.3.1  Definition of AE  
AE definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention , whether or not considered related 
to the study intervention . 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study  intervention . 
VV-CLIN-0587271 2.0Page 82
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 82 Definition of unsolicited and solicited AE  
• An unsolicited adverse event is an adverse event that was not solicited using a home 
dosing diary and that is communicated by a participant who has signed the informed 
consent. Unsolicited AEs inclu de serious and non -serious AEs.  
• Potential unsolicited AEs may be medically attended (ie, symptoms or illnesses requiring a 
hospi[INVESTIGATOR_059] , or emergency room visit, or visit to/by a health care provider). The 
participants will be instructed to contact [CONTACT_139138](s), as well as any events that, though not medically attended, are of 
participant concern. Detailed information about reported unsolicited AEs will be collected 
by [CONTACT_902939]’s records.  
• Unsolicited AEs that are not medically attended nor perceived as a concern by [CONTACT_902940].  
• Solicited  AEs are predefined local and systemic events for which the participant is 
specifically questioned, and which are noted by [CONTACT_125495].  
Events meeting  the AE definition  
• Any abnormal laboratory test results (hematology, clini cal chemistry, or urinalysis) or 
other safety assessments ( eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the Investigator ( ie, not related to progression of underlying 
disease), eg:  
- Symptomatic and/or ,  
- Requiring either corrective treatment or consultation, and/or ,  
- Leading to IMP discontinuation or modification of dosing, and/or ,  
- Fulfilling a seriousness criterion, and/or ,  
- Defined as an AESI . 
• Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study intervention  administration even though 
it may  have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention  or a concomitant medication.  
• The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfil the definition of an AE or SAE. Also, "lack of 
efficacy" or "failure of expected pharmacological action" also constitutes an AE or SAE.  
VV-CLIN-0587271 2.0Page 83
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 83 Events NOT meeting the AE definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_902941] p articipant’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
• Medical or surgical procedure ( eg, endoscopy, ap pendectomy): the condition that leads to 
the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen . 
10.3.2  Definition  of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if s erious conditions 
are met ( eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a) Results in death  
b) Is life -threatening  
The term “life-threatening ” in the definition of “serious ” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
c) Requires inpati ent hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_12332]/or treatment  that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in d oubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE 
should be considered serious.  
Hospi[INVESTIGATOR_21358] a pre-existing condition that did not worsen from 
baseline is not considered an AE.  
d) Results in persistent disabil ity/incapacity  
- The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
VV-CLIN-0587271 2.0Page 84
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 84 - This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea , vomiting, diarrhea, influenza, 
and accidental trauma ( eg, sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.  
e) Is a congenital anomaly/birth defect  
f) Other situations:  
- Medical or scient ific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_902891]. These events should usually be 
considered serious.  
- Examples of such events include invasive or malignant cancers, intensive treatment  in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.  
10.3.3  Recording and follow -up of AE and/or SAE   
AE and SAE recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all  
documentation ( eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) 
related to the event.  
• The Investigator  will then record all relevant AE/SAE information in the CRF.  
• It is not acceptable for the Investigator  to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor’s representative in lieu of completion of the AE/SAE CRF page.  
• There  may be instances when copi[INVESTIGATOR_714367] . In this case, all participant identifiers, with the exception of the participant 
number, will be redacted on the copi[INVESTIGATOR_244877] n to the 
Sponsor . 
• The Investigator  will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Assess ment of intensity  
The Investigator  will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to 1 of the following cat egories:  
• Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort and  
not interfering with everyday activities.  
VV-CLIN-0587271 2.0Page 85
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 85 • Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confus ed with a SAE. Severe is a cat egory utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.  
An event is defined as “serious ” when it meets at least 1 of the predefined outcomes as described 
in the definition of an SA E, NOT when it is rated as severe.  
Assessment of causality  
• The Investigator  is obligated to assess the relationship between study intervention  and 
each occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts, ev idence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The Investigator  will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, an d other risk 
factors, as well as the temporal relationship of the event to study intervention  
administration will be considered and investigated.  
• The Investigator  will also consult the Investigator ’s Brochure (IB) and/or Product 
Information, for marketed p roducts, in his/her assessment.  
• For each AE/SAE, the Investigator  must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator  has minimal 
information to include in the initial report to  the Sponsor’s representative . However, it is 
very important that the Investigator  always make an assessment of causality for 
every event before the initial transmission of the SAE data to the Sponsor . 
• The Investigator  may change his/her opi[INVESTIGATOR_9242] -up information 
and send a SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining r egulatory repo rting 
requirements.  
Follow -up of AEs and SAEs  
• The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_2728]’s 
representative to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -up 
period, the Investigator  will provide the Sponsor with a copy of any post -mortem findings 
including histopathology.   
• New or updated information will be recorded in the originally completed CRF.  
VV-CLIN-0587271 2.0Page 86
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 86 • The Investigator  will s ubmit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.  
10.3.4  Reporting  of SAEs  
SAE reporting to the Sponsor via an electronic data collection tool  
• The primary mechanism for reporting an SAE to the Sponsor’s representative will be the 
electronic data collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data collection 
tool (see next section)  in order to report  the event within 24 hours . 
• The site will enter the SAE data into the electronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new da ta or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken off -
line, then the site can report this informa tion on a paper SAE form (see next section) or to 
the Sponsor’s representative by [CONTACT_756].  
• Contacts for SAE reporting can be found in the protocol . 
SAE reporting to the Sponsor via paper CRF  
• Facsimile transmission of the SAE paper CRF is the preferred me thod to transmit this 
information to the  Sponsor’s representative . 
• In rare circumstances and in the absence of facsimile equipment, notification by [CONTACT_13186] a copy of the SAE data collection tool sent by [CONTACT_902942] e. 
• Initial notification via telephone does not replace the need for the Investigator  to complete 
and sign the SAE CRF pages within the designated reporting time frames.  
• Contacts for SAE reporting can be found in  the protocol . 
10.4 APPENDIX 4: CONTRACEPTIVE GUID ANCE AND COLLECTION OF PR EGNANCY 
INFORMATION   
DEFINITIONS : 
Woman of childbearing potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below).  
If fertility is unclear ( eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered.  
VV-CLIN-0587271 2.0Page 87
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 87 Women in the following cat egories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
- Documented hysterectomy  
- Documented bilateral salpi[INVESTIGATOR_1656]  
- Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than 
the above,  (eg, mullerian agenesis, androgen insensitivity), Investigator discretion 
should be applied to determining study entry.  
Note:  Documentation can come from the site personnel’s: review of the participant’s 
medical records, medical examination, or medical history interview.  
3. Postmenopausal female  
- A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
- A high follicle stimulating hormone (FSH ) level in the postmenopausal range may 
be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT ). However, in the absence of 
[ADDRESS_1266362] discontinue 
HRT to allow confirmation of postmenopausal status before study enrollment.  
CONTRACEPTION GUIDANCE : 
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year when used 
consistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationc 
- Intrauterine device (IUD)  
- Intrauterine hormone -releasing system (IUS)c 
• Bilateral tubal occlusion  
Vasectomized partner  
(Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the 
woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method 
of contraception should be used. Spermatogenesis cycle is approximately 90 days.)  
VV-CLIN-0587271 2.0Page 88
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 88 Highly Effective Methodsb That Are User Dependent Failure rate of <1% per year when used consistently and 
correctly.  
• Combined (estrogen - and progestogen -containing) hormonal contraception associate d with inhibition of ovulationc 
- oral 
- intravaginal  
- transdermal  
- injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulationc 
- oral 
- injectable  
Sexual abstinence  
(Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during  the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be 
evaluated in re lation to the duration of the study and the preferred and usual lifestyle of the participant.)  
a Contraceptive use by [CONTACT_902943].  
b Failure rate of <1% per year when used consistently and correctly.  Typi[INVESTIGATOR_21361].  
c If locally required, in accordance with Clinical Trial Facilitation Group  guidelines, acceptable contraceptive methods are limited to those 
which inhibit ovulation as the primary mode of action.  
Note: Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides only, and 
lactational amenorrhoea me thod (LAM) are not acceptable methods of contraception. Male condom and female condom should not be used 
together (due to risk of failure with friction) . 
COLLECTION OF PR EGNANCY INFORMATION :  
Male participants with partners who become pr egnant  
• The Investigator  will attempt to collect pr egnancy information on any male participant’s 
female partner who becomes pr egnant while the male participant is in this study. This 
applies only to male participants who receive study intervention . 
• After obtaining the  necessary signed informed consent from the pr egnant female partner 
directly, the Investigator  will record pr egnancy information on the appropriate form and 
submit it to the Sponsor  within 24 hours of learning of the partner’s pr egnancy. The 
female partner  will also be followed to determine the outcome of the pr egnancy. 
Information on the status of the mother and child will be forwarded to the Sponsor . 
Generally, the follow -up will be no longer than 6 to 8  weeks following the estimated 
delivery date. Any te rmination of the pr egnancy will be reported r egardless of fetal status 
(presence or absence of anomalies) or indication for the procedure.  
Female participants who become pr egnant  
• The Investigator  will collect pr egnancy information on any female participa nt who 
becomes pr egnant while participating in this study. The initial information will be 
recorded on the appropriate form and submitted to the Sponsor  within 24 hours  of learning 
of a participant ’s pregnancy.  
VV-CLIN-0587271 2.0Page 89
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 89 • The participant will be followed to determine the outcome of the pr egnancy. The 
Investigator  will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the Sponsor . Generally, follow -up will not be required 
for longer than 6 to 8 weeks beyo nd the estimated delivery date. Any termination of 
pregnancy will be reported, r egardless of fetal status (presence or absence of anomalies) or 
indication for the procedure.  
• Any pr egnancy complication or elective termination of a pr egnancy  for medical reas ons 
will be reported as an AE or SAE.  
• A spontaneous abortion  (occurring at <22 weeks gestational age) or still birth (occurring at 
>22 weeks gestational age)  is always considered to be an SAE and will be reported as 
such.  
• Any post -study pr egnancy related  SAE considered reasonably related to the study 
intervention  by [CONTACT_208051]  8.3.4 . While the Investigator  is not obligated to actively seek this information in 
former study participants, he or she may learn of an SAE through spontaneous reporting.  
• Any female participant who becomes pr egnant while participat ing in the study will 
discontinue study intervention . 
VV-CLIN-0587271 2.0Page 90
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 91 
VV-CLIN-0587271 2.0Page 92

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 92 
VV-CLIN-0587271 2.0Page 93

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 93 10.7 APPENDIX 7: SCIENCE37  METASITE   
One study center will be managed by [CONTACT_902944]37, using TM, mobile study 
nurses, and an electronic application called the Science37  Platform.  
Study participants  will undergo the same procedures and provide the same data as other trial 
partic ipants  as outlined in the protocol. The difference is that Science37 will interact with their 
participant s using an innovative model, an electronic application and/or mobile nurses.  
As part of this study, Science37 participants  will see their study doctors  by [CONTACT_2329] a TM model 
during the study. The goal of TM is to make it easier for the participant s to take part in the study. 
Telemedicine will use secure video conferences, phone calls, and a web portal and/or mobile 
application as a way of communicating wit h and monitoring participant s. Science37 will provide 
mobile study nurses to the participant’s  home or location for study procedures, rather than a 
traditional investigative site. As part of this process, an electronic application called the Science37  
Platform will be utilized for data collection.  
The Science37  Platform is an electronic application developed by [CONTACT_902897]37. The Science37  
Platform is password protected and only the study participant can access their own login. No one 
other than the participant  and the study staff is able to view personal identifiable (e.g. 
photographs) and/or trial data  in the Science37  Platform. As a function of the platform, 
information and/or photographs are transmitted to the research staff securely  via the platform. 
Data s ubmitted by [CONTACT_902945]37 mobile application (whether trial related 
information and/or photographs) are never saved locally on the device (tablet/phone). All 
information and /or photographs received by [CONTACT_902946] 37 Platform will 
be stored securely and confidentially  within the platform . A participant ’s personal use of 
information stored on the device will not be monitored. Participants  will still be able to visit all 
local doctors as they normally would, but the S cience37 study doctors and nurses will also 
communicate with the participant ’s doctor to explain the study and coordinate participant  care 
during the study. Participants  will also be provided and requested  to sign an informed consent 
document  (e-ICF) which explains rights as a participant  in the study.  Science37 Metasite 
participants will complete the consent process remotely with Science37 study staff and sign the 
eConsent in the platform, accessible via an App on a smartphone or tablet, or on a comp uter 
desktop browser. The participants will be informed that they may download and print a copy of 
the e -ICF, or a copy may be emailed to them upon the participant’s request.  
For participants enrolled through virtual site (Metasite), IMP (and some other study materials, if 
needed)  will be supplied from the virtual site to the participant via DTP service which will be 
handled and under the responsibility of Science37.  
VV-CLIN-0587271 2.0Page 94

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 94 The IMP will be administered by a mobile study nurse at the randomization dosing visit. 
Participants /caregivers  will be instructed as per Section  6.[ADDRESS_1266363]/inject 
the IMP at the first dosing visit and will be allowed to self -administer for the remainder of the 
treatment period. This training must be documented in the participant’s study file. If the 
participant is not comfortable with self -administration, the mobile study nurse wi ll perform the 
administrations at home visits at every 2 weeks , according to the scheduled IMP administrations.  
The mobile study nursing management with all related activities will be under the responsibility 
of Science37. The investigator of Metasite obt ains intervention kit numbers at randomization 
(Day  1) and subsequent scheduled visits via IVRS/IWRS.  
Science37 participant randomization in IVRS/IWRS will occur on Day  1, with first loading dose 
occurring up to 5  days after randomization to account for th e lag between IVRS/IWRS 
randomization trigger for IMP DTP shipment and IMP availability to participant/mobile study 
nurse.  
For the subsequent at home dosing visits (week  4, week  8, week  12) the window may increase up 
to 3 days (maximum visit window)  to acc ount for the lag between IVRS/IWRS trigger for IMP 
DTP shipment and IMP availability to participant/mobile study nurse.  
All intervention kits accountability and return (whether used or empty or unused) of participants 
enrolled through Metasite will be man aged and under the responsibility of Science37.  
Study procedures:  
Asthma Sleep Disturbance Questionnaire, sleep diary: the completion of the daily questionnaires 
for the baseline and for postbaseline assessments will be done as per SoA and will continue un til 
the IMP dose administrations, considering the lag between IVRS/IWRS trigger for IMP DTP 
shipment and IMP availability to participant/mobile study nurse.  
Actigraphy: the participants will perform the baseline and postbaseline assessments as per SoA 
and will continue until the day prior to IMP dose administrations.  
ADSD: will be completed by [CONTACT_902947], 
every 4  weeks.  
ANSD: will be completed by [CONTACT_902948], 
every 4  weeks.  
All the other study assessments will be done as per SoA, (see Section  1.3). 
Approximately  10 participants  will be enrolled to the Decentralized Clinical Trial Site  (DCTS ), a 
clinical trial operating model that enables remote participation in clinical trials. One DCTS in the 
US will be  included in the study. The DCTS is a remote study model that integrates TM 
technology into the clinical research process and supports management of research activities, 
including data collection. As part of this model, study visits are completed using the  DCTS 
technology platform. This 21 CFR Part 11 compliant software interface facilitates recruitment, 
VV-CLIN-0587271 2.0Page 95
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 95 enrollment, and study data collection within a single cloud -based technology. It connects 
participants  to their investigators and study team through a stud y-issued smartphone.  
Decentralizing research studies from traditional site -based centers, making them “site -less,” aims 
to eliminate participation barriers, such as  inaccessibility due to geography and the inconvenience 
of traveling to site visits. A DCTS complies with all regulatory requirements applicable to study 
investigators, as delineated in 21 CFR 312 and ICH E6 (R2). As such, it does not assume any 
Sponsor or CRO obligations.  
The participants enrolled by [CONTACT_902897]37 Metasite will not participate in . 
10.8 APPENDIX 8: CONTINGENCY MEASUR ES FOR A REGIONAL OR  NATIONAL 
EMERGENCY THAT IS DE CLARED BY A GOVERNME NTAL AGENCY   
Continuation of the study in the event of a regional or national emergency declared by a 
governmental agency:  
A regional or national emergency declared by a governmental agency (eg, public health 
emergency, natural disaster, pandemic, terrorist attack) may prevent access to the clinical trial 
site. 
Contingen cy procedures are suggested below and in sections ( Section  2.3.3 , Section  5.5, 
Section  6.1, Section  7.1.2 , Section  [IP_ADDRESS] , Section  8, Sectio n 9.4.6, Section  10.1.3 ) for an 
emergency that prevents access to the study site, to ensure the safety of the participants, to 
consider continuity of the clinical study conduct, protect trial integrity, and assist in maintaining 
compliance with Good Clinical Practice in Conduct of Clinical Trials Guidance. Sponsor 
agreement MUST be obtained prior to the implementation of these procedures for the duration of 
the emergency.  
During  the emergency, if the site will be unable to adequately follow protocol mandated 
procedures, screening  may be temporarily delayed/halted (see also Section  5.5). 
Attempts should be made to perform all  assessments in accordance with the approved protocol to 
the extent possible. In case this is not possible due to a temporary disruption caused by [CONTACT_229595], focus should be given to assessments necessary to ensure the safety of participants 
and those i mportant to preserving the main scientific value of the study.   
Procedures to be considered in the event of a regional or national emergency declared by a 
governmental agency:  
• If onsite visits are not possible  during the intervention period, the visit can be performed 
remotely ensuring at least the procedures that can be done at home: PROs completion, 
actigraphy, home (if applicable), IMP administration, blood samples collection, 
pregnancy test if applicable, safety reporting, and concomitant medication s. 
• If on -site visits are not possible visit windows may be extended for assessment of safety 
and/or efficacy data that cannot be obtained remotely  (eg, spi[INVESTIGATOR_038],  on -site 
PROs, vital signs) . 
VV-CLIN-0587271 2.0Page 96

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 96 • Use of local laboratory locations may be allowe d.  
• Arrangements can be made for qualified site personnel and/or health care professionals 
(eg, visiting nurse service) for blood sample collection and study drug administration, if 
allowed by [CONTACT_902949] -site IMP dispensing, IMP may be supplied from the site to the 
participant via a Sponsor -approved courier company where allowed by [CONTACT_718399].  
Rechallenge: In case of missed dose(s), no loading dose of  two injections will be administered 
when restarting the treatment, whatever the number of missed doses. The participants  should 
continue their scheduled IMP treatment and visits, even if more than  two consecutive doses were 
missed.  
Contingencies implemented du e to emergency will be documented.  
Statistical analysis: a sensitivity analysis may be conducted; details will be specified in the SAP.  
For a regional or national emergency declared by a governmental agency, contingency procedures 
may be implemented for t he duration of the emergency. The participants or their legally 
authorized representative should be verbally informed prior to initiating any changes that are to be 
implemented for the duration of the emergency (eg , study visit delays/treatment extension, use of 
local labs).  
10.9 APPENDIX 9: DEFINITION OF ANAP HYLAXIS   
“Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death ( 36)”. 
 
Clinical criteria for diagnosing anaphylaxis  
 
VV-CLIN-0587271 2.0Page 97
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 97 10.10  APPENDIX 10: ABBREVIATIONS   
 
ACOS:  asthma -COPD overlap syndrome  
ACQ:  asthma control questionnaire  
ACT:  asthma control test  
AD: atopic dermatitis  
ADR:  adverse drug reaction  
ADSD:  asthma daytime symptom diary  
AE: adverse event  
AESI : adverse event of special interest  
  
ALT:  alanine transaminase  
ANSD:  asthma nighttime symptom diary  
  
ATS:  American Thoracic Society  
BD: bronchodilator  
BMI:  body mass index  
CFR:  code o f federal regulations  
CI: confidence interval  
CIOMS:  Council for International Organizations of Medical Sciences  
CONSORT:  Consolidated Standards of Reporting Trials  
CRO:  contract research organization  
CRSwNP:  chronic rhinosinusitis with nasal polyps  
CSICF:  core study informed consent form  
DCTS:  decentralized clinical trial site  
DPI:  [INVESTIGATOR_902892]:  direct to participant  
E/D:  early discontinuation  
ECG:  electrocardiogram  
e-CRF:  electronic case report form  
e-ICF: electronic informed consent form  
EoE:  eosinophilic esophagitis  
EOS:  end of study  
EOT:  end of treatment  
ERS: European Respi[INVESTIGATOR_902893]:  early study discontinuation  
ETD:  early treatment discontinuation  
FDA:  Food and Drug Administration  
FeNO:  fractional exhaled nitric oxide  
FEV 1: forced exp iratory volume  
FSH:  follicle stimulating hormone  
FVC : forced vital capacity  
GCP:  Good Clinical Practice  
GDPR:  General Data Protections Regulation  
GINA:  Global Initiative for Asthma  
VV-CLIN-0587271 2.0Page 98

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 99 pMDI:  pressurized metered dose inhaler  
pre-BD FEV 1: prebronchodilator forced expi[INVESTIGATOR_902894]:  patient -reported outcome  
PROMIS:  patient -reported outcome measurement information system  
  
PSQI:  Pi[INVESTIGATOR_902895]: preferred term  
Q2W:  every 2 weeks  
RNA: ribonucleic acid  
ROW:  rest of world  
SABA:  short -acting beta2 agonist  
SAE:  serious adverse event  
SAMA : short -acting muscarinic antagonist  
SAP:  statistical analysis plan  
SARP:  severe asthma research program  
SC: subcutaneous  
SD: standard deviation  
  
SoA:  schedule of activities  
SOC:  system organ class  
  
S[LOCATION_003]R:  suspected unexpected serious adverse reaction  
TB: tuberculosis  
TEAE:  treatment -emergent adverse event  
  
ULN:  upper limit of normal  
WASO:  Wake after sleep onset  
WOCBP:  women of childbearing potential  
  
 
10.11  APPENDIX 11: PROTOCOL AMENDMENT H ISTORY   
The Protocol Amendment Summary of Changes T able for the current amendment is located 
directly before the Table of Contents.  
10.11.1  Amended protocol 01 (17 September 2020)   
This amended protocol (amendment 01) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directi ve 2001/20/EC of the European Parliament and the Council of the 
European Union.  
VV-CLIN-0587271 2.0Page 100

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 100 OVERALL RATIONALE FOR THE AMENDMENT  
The main rationale for the Amendment is the decision to perform the  
assessments in the substudy at patient’s home usin g Type II devices instead of on -site 
overnight assessments as initially planned. This decision was taken considering that the patients' 
safety is of outmost importance in the context of the coronavirus disease 2019 (COVID -19) 
pandemic with unpredictabl e evolution. In addition, an updated version of the sleep disturbance 
questionnaire has been implemented based on patient feedback to improve its understanding.  
Further updates have been done in adverse events of special interest (AESI) listing and 
Benefit /Risk assessment chapter based on the new SAR231893 Investigator's Brochure (IB) dated 
19-Jun-2020.  
Protocol amendment summary of changes table  
Section # and Name  [CONTACT_11029]  
1.1 Synopsis; 1.3 Schedule 
of Activities (SoA); 
4.1 Overall design; 
 
 
 
 
 The parameters will be assessed using 
Type II home devices instead of on -site 
 assessments.  Patients' safety is of outmost importance in the 
context of COVID -19 pandemic and its 
unpredictable evolution, thus it was decided to 
perform the assessment at home using 
Type II devices, instead of on -site overnight 
 as initially planned.   
1.1 Synopsis; 1.3 Schedu le 
of Activities (SoA); 
4.1 Overall design; 
 
 
 
 
 The  assessments will be done at home 
at two timepoints (on Day -1 and at End of 
Treatment [E OT] visit); the assessment on 
Day -2 for the control of “first night effect” 
has been removed.  The  assessment on Day -2 for the control 
of any “first night effect” is not needed in case 
of home  
1.1 Synopsis; 1.3 Schedule 
of Activities (SoA); 
4.1 Overall design; 
10.6 Appendix 6: 
Polysomnography substudy  If the sleep recording is inadequate as 
judged by [CONTACT_902905], the at -
home sleep assessment will be repeated 
within 1 week of the original assessment.  To mitigate the risk of missin g data due to 
inadequate recording  
3 Objectives and Endpoints  Exploratory endpoint:  
 
 
 
 
 Parameters added  
  
1.3 Schedule of Activities 
(SoA); 5.1 In clusion criteria; 
8.1.2 Fractional exhaled 
nitric oxide;  FeNO will be rechecked at randomization.  Ensure eligibility.  
8.3.[ADDRESS_1266364] IB.  
VV-CLIN-0587271 2.0Page 101

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 101 Section # and Name  [CONTACT_11029]  
5.1 Inclusion criteria  I04. Historical values of blood eosinophil 
count meeting the eligibility criterion I04 
measured within 6 months prior to SV1 in 
the absence of OCS treatment are allowed.  To clarify in the inclusion criterion I04 that  the 
historical values of blood eosinophil count 
measured within 6 months prior to SV1 in the 
absence of OCS treatment are allowed.  
5.2 Exclusion criteria  E18. Chronic treatment with oral 
corticosteroids (OCS) is forbidden within 
2 weeks prior to Screenin g Visit 1 (SV1).  To clarify timeframe for chronic OCS treatment 
and to avoid confounding effects on sleep 
quality assessment.  
5.2 Exclusion criteria  E23. Clarifications regarding the vaccination 
prohibition until the end of the study.  Clarification based on the comment raised by 
[CONTACT_902950] (MHRA ) (Health Authorities 
from the [LOCATION_008]).  
5.2 Exclusion criteria  E.26. Trea tment with an investigational drug 
is not allowed within 1 month or within 5 
half-lives (if known), whichever is longer, 
prior to SV1.  An interdiction of non -antibody investigational 
drugs for 2 months before SV1 is unnecessary.  
2.3.1 Risk assessment; 
2.3.2 Benefit assessment;  Updated regulatory information and safety 
information based on recent Investigator’s 
Brochure update.  Provide most recent safety data in the protocol.  
2.3.3 Benefit/risk 
assessment related to 
COVID -19; 5.5  Criteria for 
temporarily delaying 
screening, randomization, or 
study intervention 
administration; 6.1 Study 
intervention(s) administered; 
7.1.2  Temporary 
discontinuation; 
[IP_ADDRESS]  Rechallenge; 8 Study 
assessments and 
procedures; 9.4.6 Other 
analyse(s); 10.1.3 Informed 
consent proce ss; 
10.7 Appendix 7 
Contingency measures for a 
regional or national 
emergency that is declared 
by a governmental agency  Contingency measures to apply during a 
regional or national emergency declared by 
a governmental agency are described.  To ensure trial c ontinuity in case of regional or 
national emergency declared by a 
governmental agency.  
1.3 Schedule of Activities 
(SoA)  Complete physical examinations will be 
performed at SV1, V2, and V5.  The number of complete physical examinations 
has been reassessed in order to decrease the 
participants’ burden.  
1.[ADDRESS_1266365] be provided to participants at 
SV2 so that the y can start using them for 7 
days before V2.  
1.3 Schedule of Activities 
(SoA)  ACQ -[ADDRESS_1266366] 5 questions.  Correction related to the calculation of ACQ -5 
score.  
VV-CLIN-0587271 2.0Page 102

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 102 Section # and Name  [CONTACT_11029]  
6.1 Study intervention(s) 
administered; 7.1.1 
Definitive discontinuation; 
10.7 Appendix 7 
Contingency measures for a 
regional or national 
emergency that is declared 
by a governmental agency  Process in case of missed IMP doses is 
detailed.  To clarify the process in case a participant 
misses IMP adminis tration(s). The participants 
will not be prematurely discontinued from 
treatment in case they miss [ADDRESS_1266367] 
been removed  Clarification: the sentence was confusing.  
1.1 Synopsis; 9.2 Sample 
Size Determination; 
9.3 Populations for analyses; 
9.4.1 General  
considerations; 9.4.2 
Primary endpoint(s); 9.4.3 
Secondary endpoint(s); 9.4.4 
Tertiary/exploratory 
endpoint(s); 9.5 Interim 
analysis  In order to mitigate the risk of potential 
different responses based on the Sleep 
Disturbance Questionnaire before and af ter 
amendment 01, the primary analysis of 
change from baseline in sleep disturbance 
score will exclude the participants who use 
the original questionnaire at baseline. The 
number of participants randomized up to the 
implementation of this protocol amendmen t 
is limited (ie, ≤10), therefore the study 
power can be preserved at ≥89% and 
therefore no participant replacement is 
planned.  The Sleep Disturbance Questionnaire 
(assessment of primary endpoint) has been 
updated. The participants already enrolled in 
the study completed the initial version of the 
questionnaire. These participants will be 
excluded from the primary analysis to mitigate 
the risk of potential different responses before 
and after this amendment.   
8.3.[ADDRESS_1266368] be prepared  
for suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) according to local 
regulatory requirements and Sponsor policy 
and forwarded to Investigators as necessary  Correction of the instructions for the 
preparation of Investigators safety reports in 
case of S[LOCATION_003]Rs  
 
8.11 Use of data for future 
research; 10.1.3 Informed 
consent process  Details on retention and use of data for 
future research.  In agreement with current legal requirements 
and Sponsor’s policy.  
10.1.4 Data protection; 
10.1.5 Dissemination of 
clinical study data  Description of data measures for 
professionals involved in the study.  In agreement with current legal requirements 
and Sponsor’s policy.  
5.2 Exclusion criteria; 
7.1.1  Definitive 
discont inuation; 
8.3.[ADDRESS_1266369]; 
10.8 Appendix 8: Definition 
of anaphylaxis  Definition of anaphylaxis was added as an 
appendix.  Clarification.  
VV-CLIN-0587271 2.0Page 103

Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 103 Section # and Name  [CONTACT_11029]  
7.1.1 Definitive 
discontinuation; 
8.3.[ADDRESS_1266370]  Definition of baseline alanine transaminase 
(ALT) has been added.  Clarification.  
Whole document  Minor formatting, typo corrections, and 
consistency changes.  Consistency.  
 
VV-CLIN-0587271 2.0Page 104
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 104 11 REFERENCES   
1. Luyster FS, Teodorescu M, Bleecker E, Busse W, Calhoun W, Castro M, et al. Sleep quality 
and asthma control and quality of life in non -severe and severe asthma. Sleep Breath. 
2012;16(4):[ADDRESS_1266371] C, Janson C. Asthma control and asthma 
severity in relation to sleep disturbances: results of the lifegene study. Eur Respir J. 
2018;52:PA5 046. 
3. Aldrich M. Impact, presentation and diagnosis. In: Kryger MH, Roth T, Dement WC, editor. 
Principles and practice of sleep medicine. 3rd ed. Philadelphia (PA): W.B. Saunders Co.; 
2000. p. 521 -80. 
4. Engleman HM, Kingshott RN, Martin SE, Dougles NJ. Cognitive function in the sleep 
apnea/hypopnea syndrome. Sleep. 2000;[ADDRESS_1266372] 4:S102 -8. 
5. Kim HC, Young T, Matthews CG, Weber SM, Woodward AR, Palta M. Sleep disordered 
breathing and neuropsychological deficits: a population -based study. Am J Crit Care Med. 
1997;156(6):1813 -9. 
6. Curcio G, Ferrara M, De Gennaro L. Sleep loss, learning capacity and academic performance. 
Sleep Med Rev. 2006;10(5):323 -37. 
7. Smaldone A, Honig JC, By [CONTACT_490199]. Sleepless in America: inadequate sleep and relationships 
to health and well -being of our nation's children. Pediatrics. 2007;[ADDRESS_1266373] 1:S29 -37. 
8. Greenberg H, Cohen RI. Nocturnal ast hma. Curr Opin Pulm Med. 2012;18(1):[ADDRESS_1266374]. 1977;71(2):87 -92. 
10. Storms WW, Bodman SF, Nathan RA, By[INVESTIGATOR_3694] P. Nocturnal asthma symptoms may be more 
prevalent than we think. J Asthma. 1994;31(4):313 -8. 
11. Sorscher AJ. How is your sleep: A neglected topic for health care screening. J Am Board Fam 
Med. 2008;21(2):141 -8. 
12. Mastronarde JG, Wise RA, Shade DM, Olopade CO, Scharf SM, American Lung Association 
Asthma Clinical Research Centers. Sleep  quality in asthma: results of a large prospective 
clinical trial. J Asthma. 2008;45(3):183 -9. 
13. Cukic V, Lovre V, Dragisic D. Sleep disorders in patients with bronchial asthma. Mater 
Sociom ed. 2011;23(4):235 -7. 
14. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T -helper type 2 -
driven inflammation defines major subphoenotypes of asthma. Am J Respir Crit Care  Med. 
2009;180(5):388 -95. 
VV-CLIN-0587271 2.0Page 105
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: [ADDRESS_1266375] I.D, Maspero J, Wenzel S, Rabe KF, et al. Dupi[INVESTIGATOR_902896] -to-Severe Uncontrolled Asthma. N Engl J Med. 2018;3 78:2486 -96. 
16. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and Safety of 
dupi[INVESTIGATOR_125419] -Dependent Severe Asthma. N Engl J Med. 2018;378(26):2475 -
85. 
17. Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR. Epi[INVESTIGATOR_116702]: a 
longitudinal study in a [LOCATION_006] population. Sleep. 2007;30(3):274 -80. 
18. Fortier -Brochu E, Beaulieu -Bonneau S, Ivers H, Morin CM. Insomnia and daytime cognitive 
performance: a meta -analysis. Sleep Med Rev. 2012;16(1):83 -94. 
19. Lian Y, Xiao J, Liu Y, Ning L, Guan S, Ge H, et al. Associations between insomnia, sleep 
duration and poor work ability. J Psychosom Res. 2015;78(1):45 -51. 
20. Sanz de Burgoa V, Rejas J, Ojeda P, investigators of the Coste Asma study. Self -perceived 
sleep quality and quantity in adults with asthma: findings from the costeasma study. J Investig 
Allergol Clin Immunol. 2016;26(4):[ADDRESS_1266376] of Poor Sleep on Physical and Mental Health in Older Women. 
Sleep Med Clin. 2018;13(3):457 -65. 
22. Scott D, Paterson JL , Happell B. Poor sleep quality in Australian adults with comorbid 
psychological distress and physical illness. Behav Sleep Med. 2014;12(4):331 -41. 
23. Braido F, Baiardini I, Ferrando M, Scich ilone N, Santus P, Petrone A, et al. The prevalence of 
sleep impairments and predictors of sleep quality among patients with asthma. J Asthma. 
2020;12:1 -7. 
24. Smith MT, McCrae CS, Cheung J, M artin JL, Harrod CG, Heald JL, et al. Use of Actigraphy 
for the Evaluation of Sleep Disorders and Circadian Rhythm Sleep -Wake Disorders: An 
American Academy of Sleep Medicine Systematic Review, Meta -Analysis, and GRADE 
Assessment. J Clin Sleep Med. 2018;14 (7):[ADDRESS_1266377] L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupi[INVESTIGATOR_181233]. N Engl J Med. 2013;368(26):2455 -66. 
26. Sweeney J, Patterson CC, Menzies -Gow A, Niven RM, Mansur AH, Bucknall C, et al. 
Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross -sectional data 
from the optimum pa tient care research database and the British Thoracic Difficult Asthma 
Registry. Thorax. 2016;71(4):339 -46. 
27. Global Initiative for Asthma. 2020 GINA report. Global strategy for asthma manag ement and 
prevention. 2020.  
28. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation 
of spi[INVESTIGATOR_038]. Eur Respir J. 2005;26(2):319 -38. 
VV-CLIN-0587271 2.0Page 106
Amended Clinical Trial Protocol 02   22-Sep-2022  
SAR231893 -LPS16677  - dupi[INVESTIGATOR_207856]: 1 
Property of the [COMPANY_011] group - strictly confidential  Page 106 29. Gater A, Nelsen L, Fleming S, Lundy J.J, Bonner N, Hall R, et al. Assessing asthma 
symptoms in adolescents and adults: qualitative research supporting development of the 
Asthma Daily Symptom Diary. Value Healt h. 2016;9:[ADDRESS_1266378]: a randomised double -blind placebo -
controlled pi[INVESTIGATOR_30338] 2b dose -ranging trial. Lancet. 2016;388([ZIP_CODE]):31 -44. 
31. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity 
and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353 -65. 
32. Chen H, Blanc PD, Hayden M L, Bleecker ER, Chawla A, Lee JH, et al. Assessing 
productivity loss and activity impairment in severe or difficult -to-treat asthma. Value Health. 
2008;11(2):231 -9. 
33. Turner -Warwick, M. Epid emiology of nocturnal asthma. Am J Med. 1988;85(1B):6 -8. 
34. Catterall JR, Douglas NJ, Calverley PM, Brash HM, Brezinova V, Shapi[INVESTIGATOR_33596], et al. Irregular 
breathing and hypoxaemia during sleep i n chronic stable asthma. Lancet. 1982;1(8267):301 -4. 
35. Montplaisir J, Walsh J, Malo JL. Nocturnal asthma: features of attacks, sleep and breathing 
patterns. Am Rev Respir Dis. 1982;125(1):18 -22. 
36. Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, et al. 
Second symposium on the definition and management of anaphylaxis: Summary report - 
Second National Ins titute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy Clin Immunol. 2006;117:391 -7.  
VV-CLIN-0587271 2.0Page 107
Signature [CONTACT_11032]-CLIN-0587271 v2.0
lps16677-16-1-1-amended-protocol02
Approve & eSign
Approve & eSignVV-CLIN-0587271 2.0Page 108
